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Summary 
 
Background: Our goal was to facilitate prevention and control of cystic echinococcosis 
(CE) in Mongolia by measuring the disease burden and societal cost, investigating the 
zoonotic linkages, and identifying the key challenges in clinical management of CE 
with proposed improvement. The disease is caused by the larval stage of Echinococcus 
granulosus sensu lato, and transmitted between dogs and various species of ungulates 
and also transmitted to humans. In humans, large cystic lesions can occur, mainly in 
the liver and lungs. Mongolia is one of the areas most affected by CE. The numbers of 
dogs and livestock are high, and a nomadic herding lifestyle is commonly practiced 
in most parts of the country. However, existing health services in Mongolia for CE 
barely reach the targeted populations, and CE cases are only detected at a late stage. 
For adequate diagnosis and treatment, herders must often travel hundreds of 
kilometers. Surgical procedures and hospitalization, travel costs, and lifelong 
disability following complicated surgeries are common for most patients. There is 
very limited information on infection in livestock populations due to the lack of public 
slaughterhouses and animal surveillance tools in the country.  
 
Methods: We collected data on human CE cases from hospital records, statistical 
departments, and ultrasound examination records. Estimates of the reported 
incidence were used to calculate disability-adjusted life years (DALYs). To estimate 
the economic cost, we interviewed 65 patients who had CE surgery. The societal cost, 
including direct medical, direct non-medical and indirect costs, was estimated. We 
investigated the zoonotic linkages using the data of surgical CE cases and the livestock 
population of four species, including sheep, goats, cattle, and camels. To support the 
statistical analysis, samples were collected from CE infected animals in an endemic 
province. The subspecies identification, genetic diversity and haplotype network 
analysis were conducted. To understand the current clinical management of CE, we 
organized Focus Group Discussions (FGD), surveyed health professionals using a 
questionnaire. The ultrasound cyst images were reviewed by international experts to 
critically contrast current national practice with WHO-Informal Working Group on 
Echinococcosis (WHO-IWGE) guideline. Key challenges and further potential 
improvements were discussed during a workshop with Mongolian and international 
experts to reach consensus for standardization of clinical practice.  
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Result: The incidence of surgical cases, diagnosed cases, and total cases including 
undiagnosed cases was estimated to be 2.2 per 100 000, 15 per 100 000 and 60 per 100 
000 person-years, respectively. The DALY was estimated to be 11461 for total cases 
including undiagnosed cases and 3017 for diagnosed cases.  
The total societal cost due to human CE is US$2.7 million which equals 0.024% 
of total gross domestic product (GDP). The cost decreases to US$0.3million when the 
productivity loss of undiagnosed and diagnosed cases is excluded. The impact on the 
household economies is high for surgical cases where 76% of the direct cost is paid by 
the patients. In total out-of-pocket expense, the cost of albendazole contributed most.  
US images of 84 patients were staged and assessed for interrater-agreement. 
The average raw agreement was 77.2%. Unweighted Kappa coefficient and weighted 
Kappa was 0.57 and 0.59, respectively. Mean proportion of images judged as stages 
CE1, CE2, CE3a, CE3b, CE4 and CL were 0.59, 0.01, 0.19, 0.08, 0.03 and 0.11 
respectively. 40 cysts met the inclusion criteria of treatment modality analysis. The 
mean proportion of cases with a single cyst assigned to medical, percutaneous 
treatment, surgery and watch & wait were 52.5% (95% CI 42-65), 25.8% (95% CI 15-
30), 5.1% (95% CI 0-10) and 3.3% (95% CI 0.0-10), respectively. 13.3% (95% CI 5–25) of 
cysts were staged as CL and therefore assigned to further diagnostic requirement. 
    
     
       
         
        
      
      
    
    
    
  
 
Conclusion: This is the first estimate of the burden and societal cost of human CE in 
Mongolia. Mongolia has a substantial proportion of the population suffering from 
cystic echinococcosis. The disease causes a significant amount of loss to society and 
household economy. Access to fully equipped treatment centers is limited by 
geographic distance and economic resources. Availability of albendazole is sparse, 
 The incidence of surgical CE cases increased by a factor of 1.71 for one 
in terquarti le range increment in the density of the camel population. No signiÞ cant
association was observed wi th other l ivestock species. The samples collected from 96 
camels and 15 goats in  an endemic region showed a CE prevalence of 19.7%and 6.7%, 
respectively. A l l l ivestock CE were caused by E.granulosus s.l. G6/ 7 (formerly
identiÞed asE.granulosuscanadensisG6/ 7) of the of the E. granulosuss.l. complex. Four  
haplotypes were identified wi thin  the l ivestock samples, two of which had not been 
previously reported. A common haplotype was identified between humans, camels, 
goats, and a wolf, al l of which were wi thin  the same geographical area. A mixed
in fection of  E. granulosus s.l. G6/ G7 wi th diff erent haplotypes in  the in termediate 
host was identified Þr st time.
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and the price is high. WHO-IWGE guidelines are not implemented for allocating 
patients within the four treatment options based on CE cyst staging, with the result 
that all CE patients are referred for surgical treatment. This creates an unnecessary 
high-risk approach for patients who could either be treated with albendazole or 
percutaneously or observed. Our study revealed evidence that camels play an 
important role contributing to human CE in Mongolia, which is a critical information 
for further control and prevention of CE. 
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1. Introduction 
 
       
    
     
   
       
           
      
     
        
     
  
 
 
 
 
Cystic echinococcosis (CE) caused by the larval stage of Echinococcosis granulosus is a 
zoonotic disease with a substantial economic impact on the human and animal health 
sectors globally (Torgerson, 2003; Budke et al., 2006; Torgerson et al., 2015). The adult
stage of the parasite resides in the intestine of the definitive host` mainly domestic
dogs` and parasite eggs are excreted into the environment with host feces. Eggs
ingested by intermediate host species mostly livestock then develop into hydatid cysts
in the liver and lung (Romig et al., 2017). An endemic situation in the animal host
increases the risk of infection in humans` who are considered aberrant intermediate 
hosts. Progression of symptoms in humans is chronic and can take months to years
until diagnosis` depending on the cyst location` size` numbers and host immune 
reactivity (Romig et al., 1986; Wang et al., 2006) (Figure 1).
Figure 1. Transmission cycle of cyst ic echinococcosis. ENV.-environment
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Most CE patients are from rural` remote areas where they have close contact with host 
animals (Li et al., 2015). Especially in semi-arid zones with water scarcity hand 
hygiene is often poor and contributes to the risk of transmission of E. granulosus eggs 
to humans.  
The disease distributed globally. More endemic areas are the eastern part of the 
Mediterranean region, northern Africa, southern and eastern Europe, at the southern 
tip of South America, in Central Asia, Siberia and western China (Deplazes et al., 
2017). Many countries that are highly potential to be endemic are, however, still not 
accounted as endemic due to the underreporting (Figure 2).  
         
Figure 2.  Current incidence of human cystic echinococcosis in Asia (Deplazes et al., 
2017) 
 
Disease understanding and effective control strategy is still a challenge for 
echinococcosis especially in developing countries (Craig et al., 2017). Due to the 
chronic nature of the symptoms, patient remoteness, absence of local diagnostic 
capability, and lack of  ineffective treatment, the CE burden is largely underestimated 
(Brunetti et al., 2011; Budke et al., 2017; Tamarozzi et al., 2017).  
The current estimated global burden for CE is an annual loss of 184`000 
disability-adjusted life years (DALYs) not accounting for the undiagnosed population 
or 1.77 million DALYs including the undiagnosed proportion (Torgerson et al., 2015). 
Figure 10 Current incidence of human cystic echinococcosis in Asia. The detailed infor-
mation (incidence data in each jurisdiction) is listed in Table S10 of the Supplementary
Material.
Table 9 Genotypes of Echinococcus spp. causing cystic echinococcosis in North Asia
(i cluding the European part of Russia), Central Asia and Caucasus (no data found in
the missing countries): Echinococcus granulosus (G1e3), Echinococcus equinus (G4),
Echinococcus ortleppi (G5), Echinococcus intermedius (G6/7) and Echinococcus
canadensis (G8, G10)
Country Human
Wolf (W),
Dog (D)
Sheep (S),
Goat (G) Cervids Pig Cattle Other
Russian
Federation
G1e3,
G6
G101,2
W: G6 and
G101
G1e31 G6, G8,
G10
Cat:
G13
Kazakhstan D: G1,
G6/74,5,6
Kyrgyzstan D: G1, G4,
G6/77
Armenia G1e38 S: G1e38 G79 G1e38
1 (Konyaev et al., 2013); 2 (Sharma et al., 2013); 3 (Konyaev et al., 2012b); 4 (Stefanic et al., 2004);
5 (Boufana et al., 2015a); 6 (Trachsel et al., 2007); 7 (Ziadinov et al., 2008); 8 Ebi, Gevorgyan H.S.,
personal communication; 9 (Snabel et al., 2009).
Global Distribution of Alveolar and Cystic Echinococcosis 399
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To fully quantify the burden in both the human and animal sectors, economic loss has 
been measured in some endemic countries, including Europe,  Middle East, South 
America countries and China (Torgerson et al., 2000; Torgerson et al., 2001; 
Majorowski et al., 2005; Benner et al., 2010; Fasihi Harandi et al., 2012; Wang et al., 
2012; Bingham et al., 2016). 
The incubation period could last from months to years depending on the age 
of the patients, cyst location, number, immunological reaction (Romig et al., 1986). It 
is not well understood which exact factors affecting the growth and progression of the 
hydatid cyst (Romig et al., 1986; Frider et al., 1999; Wang et al., 2006). Due to the silent 
or asymptomatic gradual growth of the hydatid cyst, patients either hospitalized in 
the advanced stage, or detected due to accidental findings. The organ involvement 
has a key role in the symptom of the patient (Budke et al., 2013). Recent findings 
suggesting that organ involvement could be due to genetic subspecies of E.granulosus 
(Cucher et al., 2016). The main organ affected is the liver while around 20% affected 
the lung with or without liver. A much smaller percentage affects spleen, brain, 
kidney, bone, peritoneum (Kern et al., 2017). Treatment choice can vary due to cyst 
stages and activity (Hosch et al., 2007; Hosch et al., 2008).  
Ultrasonography has developed into a powerful tool for diagnosing and 
staging CE (Brunetti et al., 2010; Stojkovic et al., 2012). There two main staging 
algorithm used in the world: Gharbi et al., (1981) and WHO-CE classification 
recommended by the WHO – Informal Working Group on Echinococosis (WHO-
IWGE) (Gharbi et al., 1981; Brunetti et al., 2010). The updated version from WHO-
IWGE has an advantage of using stage specific treatment options and accounts the re-
activation of the cyst which can change the whole prognosis of the patient. The core 
piece of the guidelines is to triage on the basis of ultrasound-defined cyst stages into 
four groups: medical, percutaneous, surgical treatment (active cyst stage CE1 to CE3b) 
and ‘watch & wait’ (inactive cyst stages CE4 and CE5) (Junghanss et al., 2008; Brunetti 
et al., 2010; Piccoli et al., 2014; Stojković et al., 2014; Stojkovic et al., 2016). The 
classification is still grossly underused in most epidemic countries (Del Carpio et al., 
2012; Tamarozzi et al., 2014; Nabarro et al., 2015). 
Based on the global public health challenge faces due to CE, WHO and its 
collaborating experts’ have proposed the global strategy: (i) make a critical assessment 
on the potential for control of cestode zoonoses focusing on the regions where the 
populations are at highest risk; (ii) establishing a research and validation agenda on 
new approaches and tools for study and control of the disease; (iii) developing a work-
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plan of action targeting interventions; and (iv) exploiting more resources, favourable 
public policy, and control options and strategies against echinococcosis (WHO, 2001; 
Torgerson and Budke, 2003; Xiao et al., 2013).  
Mongolia is one of the CE endemic countries. The country has a vast 
distribution of host animals, strong behavioral risks, and a high prevalence of 
unregulated slaughtering practice in the absence of control action in last three decades 
(Ebright et al., 2003). The most vulnerable group for CE are likely to be herder 
communities who cannot afford the treatment and transport cost. Due to the poor 
reporting system and late diagnosis, information regarding the epidemiology of CE is 
scarce. Current prevalence, distribution, algorithm of clinical case management and 
cost caused by the disease are not known (Gurbadam et al., 2010).  
 
1.1 Background of Mongolia 
Mongolia is a land-locked country in the heart of Central Asia with China to the South, 
and Russia to the North.  With a surface area of 1.5 million km  with a population of 
only 3 million, it is the word's most sparsely populated independent country. The 
geography is comparatively diverse, including wide areas of desert, mountainous and 
flat steppe regions. The climate is continental with long cold winters and short 
summers with temperatures ranging from approximately -30 C to  30 C. One third of 
the population is comprised of nomadic herders. Currently, more than 60 million 
livestock are used for the nomadic livestock husbandry.  
1.2 Previous knowledge on CE in Mongolia  
In Mongolia, the study of CE started from the 1930s onwards with the collaboration 
of Russian scientists. In 1938, Mongolia had ranked first in the world in regard to the 
prevalence of CE in livestock (Polikova, 1939). In 1926-1931, CE detected in livestock 
was with a prevalence ranging between 20-60% in the slaughterhouses (Polikova, 
1939).  The prevalence of CE in dogs was between 10-51% among rural dogs and 26% 
among city dogs (Galbadrakh, 1972). Another study was conducted in 1970 in 9 
provinces and cities of Mongolia. The results came as follows: 16% of dogs were 
positive for CE test in rural areas, 9.7% in Ulaanbaatar (UB) city. Sheep were reported 
as the highest prevalent among livestock (7.6%). Both livestock and dog prevalence 
were high in the northern provinces. The study concluded that the interaction 
2
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between sheep and dogs is the main component in the transmission of CE (Udev, 1960; 
Jezek et al., 1971; Jezek et al., 1973).  
Between 1950-1980, intensive public health and veterinary measures were taken to 
strengthen the control of the disease and to improve hygiene and sanitation. At the 
same time, there has been a huge improvement in the study and practice of diagnosing 
and surgery of human echinococcosis. In 1970s, human echinococcosis was studied by 
senior clinicians (Goosh, 1971; Khairulla, 1972; Shagdarsuren et al., 1973; Onkhuudai, 
1988). A classification system of echinococcosis was introduced in a retrospective 
study of complicated cases of echinococcosis (Sodov, 1990; Munkhtogoo, 1991). 
Surgical cases of echinococcosis among total surgical cases decreased from 7.2% to 
3.2% during 1953-1970 (Galbadrakh, 1972).  
Due to the economic collapse in 1990, centralized strategic actions of veterinary and 
public health sector weakened. Diagnosing, reporting of echinococcosis became a 
great challenge, which eventually led to underreporting. In 1993, it was reported that 
18% of the all general surgical cases were caused by echinococcosis in the First Central 
Hospital (FCH) (Davaatseren et al., 1995; Gurbadam et al., 2010).  
Current information regarding the epidemiology of CE in human is scarce. Except a 
few serological pilot study report, the prevalence, incidence information is very scarce 
(Watson-Jones et al., 1997; Huh et al., 2006). Molecular genetical investigations 
identified both E. granulosus and E. multilocularis in the cystic samples taken from the 
patients who had surgery. The G1 (E.granulosus sensu stricto) and G6-7 (E.canadensis) 
strains of E. granulosus were identified from Mongolian patients (Ito et al., 2010; Jabbar 
et al., 2011; Ito et al., 2014).  
 
1.3 Health system of Mongolia 
The current health system functions in a centralized way. Due to geographical 
isolation, and lack of human resource, the system considered to be most practical. 
Most diseases, outbreaks reported, managed in this system (Figure 3). 
	 6	
Figure 3. The health system of Mongolia (Tsilaanjav et al., 2013). Aimag-Province; 
Soum-subdivision of province; Bagh –smallest administrative unit. 
 
But for neglected diseases as CE, there is a gap. Because so far there is no official 
reports while all the signs of endemicity for CE is apparent in a great amount. This 
could be due to slow growth rate of cysts, the often uneventful clinical course until 
the cysts have reached a size or complications. On the other hand, technical capacity 
to provide the required diagnostic and surgical means at the local level is lacking. 
More so, clinical management provided for CE patient is very limited. In consequense, 
herders have to travel over hundreds of kilometres. Cost incurring travel, surgery and 
hospitalization are for many patients out of reach and lifelong disability is common. 
At central level, neither a national policy nor national guidelines for surveillance, 
prevention and case management of CE exist. Patients are more likely to be detected 
by surgical departments and missed out from the surveillance of zoonotic disease. 
Better knowledge of the burden of disease, social cost and an effective control will 
contribute to a better approach to reduce the burden of this zoonosis in Mongolia 
(WHO, 2013). Therefore, the aim of this work is to review the current situation, burden 
of human CE, its epidemiology and assess the clinical management; and to estimate 
the public and private cost of CE.  
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2.  Goals and objectives: 
Goal of this project was to contribute in the improvement of prevention and control 
of cystic echinococcosis (CE) in Mongolia by measuring the disease burden, societal 
cost, investigating zoonotic linkage, and identify the clinical management of CE with 
proposed improvement. 
Objectives: 
- Estimate burden, societal cost of CE in Mongolia 
- Understand the zoonotic linkage of CE in Mongolia based on the 
currently available data 
- Optimize the clinical algorithm of CE in Mongolia   
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3.1 Abstract 
 
Background: Cystic echinococcosis (CE) caused by the larval stage of Echinococcosis 
granulosus is a zoonotic disease with a substantial economic impact on the human and 
animal health sectors globally. Mongolia is one of the areas most affected by CE. 
However, the lack of information about disease situation, its implication on the 
country economy is not well understood which hinders future action on CE control 
and prevention. 
 
Method: We collected data on human CE cases from statistical departments, and 
ultrasound examination records. Estimates of the reported incidence were used to 
calculate disability-adjusted life years (DALYs). To estimate the economic cost, we 
interviewed  patients who had CE surgery. The societal cost, including direct medical, 
direct non-medical and indirect costs, was estimated.  
 
Result: The total societal cost due to human CE is US$2.7 million which equals 0.024% 
of total gross domestic product (GDP). The cost decreases to US$0.3million when the 
productivity loss of undiagnosed and diagnosed cases is excluded. The impact on the 
household economies is high for surgical cases where 76% of the direct cost is paid by 
the patients. The cost of albendazole contributed most in total out-of-pocket expense. 
The DALY was estimated to be 11461 for total cases including undiagnosed cases and 
3017 for diagnosed cases.  
 
Conclusion: This is the first estimate of the burden and societal cost of human CE in 
Mongolia. Mongolia has a substantial proportion of the population suffering from CE. 
The disease causes a significant amount of loss to society and household economy. 
Access to fully equipped treatment centers is limited by geographic distance and 
economic resources. Availability of albendazole is sparse, and the price is high. 
Further research on cost-effective prevention strategy is needed. 
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3.2 Introduction 
 
Cystic echinococcosis (CE) caused by the larval stage of Echinococcosis granulosus is a 
zoonotic disease with a substantial economic impact on the human and animal health 
sectors globally (Torgerson, 2003; Budke et al., 2006; Torgerson et al., 2015). The adult 
stage of the parasite resides in the intestine of the definitive host, mainly domestic 
dogs, and parasite eggs are excreted into the environment with host feces. Eggs 
ingested by intermediate host species, mostly livestock,  then develop into hydatid 
cysts in the liver and lung (Romig et al., 2017). An endemic situation in the animal 
host increases the risk of infection in humans, who are considered aberrant 
intermediate hosts. Progression of symptoms in humans is chronic and can take 
months to years until diagnosis, depending on the cyst location, size, numbers and 
host immune reactivity (Romig et al., 1986; Wang et al., 2006). Most CE patients are 
from   remote rural areas where they have close contact with host animals (Li et al., 
2015). Especially in semi-arid zones with water scarcity hand hygiene is often poor 
and contributes to the risk of transmission of E. granulosus eggs to humans. Due to the 
chronic nature of the symptoms, patient remoteness, absence of local diagnostic 
capability and lack of or ineffective treatment the CE burden is largely underestimated 
(Brunetti et al., 2011; Budke et al., 2017; Tamarozzi et al., 2017).  
     
       
     
      
      
      
     
    
        
   
      
     
       
        
  
CE is endemic in Mongolia. The country has a large and widely distributed host 
animal population, as well as strong behavioral risks, while a high degree of 
12
 Currently epidemiological data available for CE are mostly derived from
patients who seek health care after a cyst rupturesor becomes large enough to cause 
severe symptoms which are only a fraction of all  infected people (Feng et al., 2015; 
Counotte et al., 2016; Deplazes et al., 2017). A small  number of community surveys
conducted in  only a few  regions were used to extrapolate the undiagnosed
population. The cur rent estimated global burden for CE is an annual loss of 184,000 
disabi l ity-adjusted life  years (DALYs) not accounting for the undiagnosed population 
or 1.77 mi l lion DALYs including the undiagnosed proportion (Torgerson et al., 2015). 
To ful ly quantify the burden in both the human and animal sectors economic loss has
been measured in some endemic countries‘  including Europe, M iddle East, South 
American countries and China(Torgerson et al., 2000; Torgerson et al., 2001; 
Majorowski et al., 2005; Benner et al., 2010; Fasihi  Harandi et al., 2012; Wang et al., 
2012; Bingham et al., 2016). The estimation of the economic loss in  humans is based on 
the cost-of-i l lness (COI) method whereasthe economic loss for animal sectors is based
on measuring  animal productivity (Torgerson et al., 2001; Narrod et al., 2012).
	 	
       
      
   
     
    
     
    
      
       
      
     
      
      
     
 
Measurement of the epidemiologic burden in DALYs and the economic burden 
as monetary losses in the human and animal health sectors from available data could 
show the magnitude of the societal burden and provide valuable information for 
decision makers (Torgerson, 2003; Torgerson et al., 2015). A lack of available data in 
many endemic countries obscures the real magnitude of CE and challenges prevention 
and control efforts nationally and internationally (Torgerson and Budke, 2003). This 
study aimed to measure the CE burden in Mongolia for the first time by 
comprehensively assessing the available data to measure DALYs and estimate the cost 
of disease in humans. It was not possible to estimate the livestock sector burden due 
to an absence of data on animal prevalence. 
 
3.3 Materials and methods 
 
Ethical statement 
The study was approved by the Medical Ethics committee of Mongolia, the World 
Health Organization (WHO) Research Ethics Review Committee (ERC) and the Ethics 
Committee of North-Western and Central Switzerland (EKNZ 2014-240). Permission 
to access hospital and statistical data was obtained. Verbal and written informed 
consent was given by each interviewed patient. Collected data were only available to 
the study team. All patient data were rendered anonymous prior to further analysis.  
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unregulated slaughtering is ongoing w ith no control actions over the last three 
decades (Ebright et al., 2003). A crucial detrimental factor for the control of CE was
the sudden privatization of the veterinary sector fol low ing the economic col lapse of 
the Soviet Union (Ebright et al., 2003). Curren tly, reporting on CE prevalence in  the 
animal population is absent, while  there are still  many surgical CE cases, especial ly in  
the chi ldren, wh ich indicates ongoing transmission (Bold et al., 2018a). Recent
statistical analysis and molecular  genetic studies, however, suggest the importance of 
camels in  causing human CE (Bold et al., 2019). In humans, the numbers of surgical 
cases are the only avai lable data. There is no report on non-surgical cases detected
through ultrasound. Rural populations have l imited access to CE management
because the only tertiary hospital for surgical treatment is located in Ulaanbaatar 
(Bold et al., 2018a). The secondary level hospitals in rural areasare capable of detecting
CE by ultrasound, depending on the radiologists experience, but have no trained
personnel for CE surgery. Hospital izations due to CE are, therefore, rare in secondary
hospitals.
	 	
 
3.3.1 Data collection 
 
Epidemiological data 
Surgical cases: There is no official report on the number of surgical cases. Data from 
CE cases reported from 2006-2016 were extracted from the database of Center for 
Health Development next to Ministry of Health, Mongolia. Diagnoses recorded as 
ICD code 67.1-67.9 were compiled, along with patient age, sex, registration number, 
residential province, admission date, hospital name, and category of treatment given. 
Non-surgical cases: Each Mongolian province has a single secondary level 
hospital (Provincial General Hospital). In each secondary hospital, two or three 
radiologists conduct ultrasound examinations on patients with abdominal symptoms. 
Pathognomonic hydatid cysts are generally identified initially at this level and 
subsequently referred to tertiary hospitals if necessary (e.g., for advanced diagnostics 
or surgery). There is currently no algorithm utilized to identify or stage CE hydatid 
cysts in Mongolia. Diagnostic methods including the Gharbi classification or WHO 
Informal Working Group on Echinococcosis (IWGE) classifications are not 
implemented in the provinces, which allows for uncertainty in the clinical 
management (Bold et al.; Brunetti et al., 2010). Hydatid cysts located extra-
abdominally are highly likely to be misdiagnosed or sent directly to a tertiary hospital 
for further diagnostics without specifying any diagnosis at the secondary level. The 
retrospective data collection of ultrasound examination failed to give information of 
consistent data due to paper-based archive maintenance. Therefore, we collaborated 
with radiologists from eight provincial hospitals and recorded new 
ultrasonographically diagnosed cases for one year (2016) using an online data 
collection tool developed for this study. To reduce misdiagnosing, radiologists who 
had been working for more than 10 years were recruited for the study. Anonymized 
patient information was recorded, including age, sex, cyst location, features in the 
imaging, and treatment recommendation. A paper copy of the online form was sent 
to personnel at the local center for zoonotic disease and entered a second time. Since 
fully calcified cases do not need treatment and are not referred, we excluded all cases 
diagnosed with full calcification.  
Undiagnosed/non-healthcare seeking cases: Due to the geographical limitation 
and asymptomatic nature of the disease, a large fraction of all infected patients are not 
detected by the health system. Previous studies in other endemic areas used 
! "
	 	
     
       
      
     
     
    
      
  
 
          
         
        
      
      
       
        
      
    
    
      
        
 
In Mongolia, CE surgery only conducted in public hospitals. Patients have to 
pay 10-15% of the medical charges in public hospitals, except for emergency care, or 
during mass outbreak of infectious diseases. People with disabilities, pensioners, and 
children under 16 are exempt from these user-fees. In addition, most diagnostic costs 
above US$ 20 are paid by the patients (Tsilaanjav et al., 2013). In general, due to the 
long waiting time and overloaded queue for diagnostics in the public hospitals, 
patients from rural areas often go to private hospitals for diagnostics, to reduce the 
waiting time. Therefore, we divided direct medical costs, into direct medical public 
cost and direct medical private cost. In addition, direct non-medical costs and income 
loss were calculated (WHO, 2016). Patient interviews were the main source of the cost 
information for surgical and non-surgical patients, with a few exceptions.  Fixed 
values were used for the unit daily costs of accommodation in the city and of a hospital 
15
community surveys to estimate the number of inf ected people. The ratio between the 
numbers of undiagnosed and diagnosed casesmay range between 2 and10, based on 
the large scale communi ty survey in  China (Li et al., 2013; Osman et al., 2014; Feng et
al., 2015; Deplazes et al., 2017). In Mongolia, however, there was only one survey
conducted 14 years ago in  a single Ò soum Ó  (subdivision of province) which was not
representative for extrapolation to country level (Wang et al., 2005). Therefore, 
extrapolation of undiagnosed cases was based on the proportion of cl in ical casesand
the in formation in the l iterature on the average length of the incubation period of CE. 
Cost
Patient interviews were conducted to record the amount of money and time spent to
get health care due to CE. Patientswho were hospitalized for CEsurgery at the tertiary
hospitals from 2010-2016 were contacted by local cl inicians and invited to participate 
in  the study. Patients who agreed to participate received a verbal and w ritten 
explanation of the consent form by a member study team. If the patient was a chi ld, a 
parent was asked for permission and gave consent. Patients who gave consent were 
in terviewed at their nearest health facil ity. 75% of the patients who agreed to
participate were hospitalized duri ng 2013-2016. Patient interviews were conducted
from 2014 to 2016. The in terview  questions included age, year of hospital ization, 
accompanying caretaker, number of visits to the hospital, travel and accommodation 
costs, and payments for diagnostic tests and treatments. To calculate the income loss, 
we asked about patients‘ and family members, income from salary or welfare and
coping mechanisms dur ing the health-care seeking  period (Table S1).
	 	
     
 
 
Direct medical public cost: Direct public costs consist of the cost of the hospital stay, 
cost of diagnostics under US$ 20 including ultrasonography, radiography, blood tests. 
The cost was calculated for both surgical and non-surgical patients. 
 
    
   
  
   
     
     
    
        
      
       
 
 
Direct non-medical cost: Depending on the patient’s health status and distance from 
the tertiary hospital, different modes of transport were used including train, car, 
public bus, and airplane. We included the proportion of caretakers in the computation 
of average transportation cost. In addition, the meal and accommodation costs for 
stays in the capital city for CE surgery were included in this category. For non-surgical 
cases, the meal and accommodation costs were assumed to be zero and travel costs 
were limited to primary and secondary health care centers. 
 
Indirect cost: Time spent in the capital city for CE surgery for patients with salary and 
accompanying caretakers with salary were calculated as income loss. To determine 
the household income loss, the daily income was calculated based on income from 
welfare, salary and private business. We asked about coping mechanisms during the 
hospitalization for CE when patients had insufficient money. For those who received 
bank loans discounted, interest payments were calculated as losses. We did not 
measure productivity loss for surgical and non-surgical cases, or undiagnosed cases. 
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Direct medical private cost (out-of-pocket expense): Direct private costs include the 
cost of albendazole treatment, an admission fee which includes a 10-15% user-charge 
and surgical materials (drainage, bandages), the informal fee for surgeons, informal 
fee for nurses, physiotherapy during the hospitalization (acupuncture, UV therapy, 
massage) and diagnostics above US$20 (computed tomography scans, cancer 
markers). The direct private cost was calculated for both surgical and non-surgical 
patients. The information on cost of albendazole for non-surgical cases could not be 
obtained. Albendazole is used as a complementary to surgery not as a separate 
treatment option, mainly due to unavailability at the rural hospitals. The cost of 
albendazole of surgical patients was applied to non-surgical patients assuming them
all to need treatment with albendazole .
stay (Table S1). For undiagnosed cases, a lossof productivity, asbased on the l iterature 
values, was applied (Benner et al., 2010).
	 	
Therefore, previously reported productivity loss estimate of  0.015 for undiagnosed 
cases was used for all cases and reported separately (Benner et al., 2010).  
 
3.3.2 Data analysis 
 
Estimating the human cases 
Our calculations were restricted to patients without calcifications as these do not need 
treatment. Moreover, we first disregarded pulmonary cases. The number of diagnosed 
non-pulmonary cases could be retrieved for 8 provinces in 2016. The number of 
diagnosed but not surgically treated non-pulmonary cases in 2016 was calculated as 
the difference between the number of reported non-pulmonary cases and the number 
of non-pulmonary  surgical cases which were not accidentally detected at the surgical 
clinic. These differences were fitted by a Quasi-Poisson regression model including 
the natural logarithm of the average annual count of non-pulmonary surgical cases 
over the period 2012-2016 in the respective province as independent variable. The 
model was used to predict the number of diagnosed non-surgical and non-pulmonary 
cases in 2016 across the other provinces. For the respective numbers in the 8 provinces 
with existing data, we did not just use the reported figures but  computed empirical 
Bayes estimates according to the formula.  
  𝑦"#$ = 𝑤$𝑦$ + (1 − 𝑤$)𝑦$  
where 𝑦$ and  𝑦$ denote the recorded and fitted numbers, respectively, of non-
surgical non-pulmonary cases in province i and  𝑤$ = 𝑦$ 𝑦$ + 𝑆𝐸(𝑦$)..  
  
In a similar way, an empirical Bayes estimate was computed for the average annual 
number of non-pulmonary surgical cases in 2016 using the prediction provided by a 
Quasi-Poisson regression model with a linear time trend variable having been fitted 
to the annual numbers of surgical cases between 2006 and 2016. 
  The numbers of non-pulmonary surgical and non-surgical cases in 2018 were 
then estimated by multiplying their estimates for 2016 by the factor exp 2𝛽 , with 𝛽 
denoting the coefficient of the variable year in the aforementioned model.  
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95%-con Þ dence intervals were computed for the estimated numbers of non-
pulmonary cases in 2018by simulating the uncertainty around the point estimates.
For this purpose, we distinguished the number n of surgical cases, the number n of
	 	
non-surgical cases in the provinces without data on non-surgical cases, and the 
number n of non-surgical cases in the eight provinces which provided data on these 
cases in 2016. The simulation consisted in first adding a random term	𝑆𝐸(𝑦) ∙ 𝑧8 to the 
respective point estimate 𝑦  with z being sampled from the standard normal 
distribution, and then multiplying this sum by exp	(2𝛽) ∙ (1 + 2𝑆𝐸 𝛽 𝑧.)  with z  being 
another standard normal random number. The standard error of the estimate of n  
included two components, the first one relating to the uncertainty of the regression 
model and the second one to the uncertainty associated with the over-dispersion of 
provincial counts. 
In a further step, the estimated counts of non-pulmonary surgical and non-
surgical cases were divided by the proportion  𝑝:; of non-pulmonary surgical cases 
to obtain estimates of all clinical cases. To take into account the statistical uncertainty 
introduced by this factor, these estimates were multiplied by the factor  1 − <"(=>?)=>? 𝑧@, 
with 𝑆𝐸(𝑝:;) denoting the standard error of 𝑝:; and 𝑧@ a further standard normal 
random number. 
   
   
For the estimation of the number of undiagnosed cases, we assumed the average time 
from infection to diagnosis to be 5 years in adults and 2 years in children. Accordingly, 
the number of undiagnosed adult cases was estimated to be 4 times the number of 
diagnosed cases, and the respective number in children was assumed to equal the one 
for the diagnosed children.    
 
Cost estimates 
Different types of costs and frequencies were assessed in an interview among the 
surgical cases in 2016, enabling estimating mean individual values for these variables 
along with their standard errors.  
To obtain confidence intervals for the mean individual amounts of different 
types of costs, point estimates 𝑐 from the cost survey were replaced by  𝑐 + 𝑆𝐸(𝑐) ∙𝑡(𝑘 − 1) in the respective formulas, with k denoting the number of reports of the 
respective cost item in the survey and 𝑡(𝑘 − 1) a random number sampled from the t-
distribution with k-1 degrees of freedom. Frequencies were treated in the same way.  
After 1000,000 iterations of adding random terms to the point estimates of case 
18
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After iterating these simulation steps 1000,000 times, the 95%-confidence limits
were estimated by the 2.5  and the 97.5 percentiles of simulated values.th t h
	 	
numbers, costs and frequencies across cost formulas, 95%-confidence limits were 
determined as described above for the case numbers.  
Based on the data from surgical cases, the proportion of adult cases was 
estimated to be 60%. If mean costs or frequencies could not be estimated from the 
survey, estimates were derived from published data. Uncertainties were ignored for 
these quantities. 
  
DALY estimates 
The DALY is the summary measure of public health used to quantify the burden of 
disease and it is the key measure for Global Burden of Disease estimate.  The main 
components of DALYs are the years lived with disability (YLD) and the years of life 
lost due to premature mortality (YLL). In DALY estimation, disability is measured 
from 0 to 1, with 0 representing perfect health and 1 death. The proportion of reduced 
health due to illness is defined as Disability Weight (DW). The formula for the 
calculations are the following (Devleesschauwer et al., 2014b): 
 
DALY=YLL+YLD 
YLD= Number of cases * duration till remission or death * DW 
YLL= Number of deaths * life expectancy at the age of death 
 
We estimated DALY for all persons having been infected with the disease irrespective 
of whether they were diagnosed or not. The duration of illness was assumed to be 
lifelong for all categories and approximated by the life expectancy at the mean age of 
diagnosis (i.e., 23 years), differentiating between men and women (Torgerson et al., 
2015). A DW of 0.123 was assumed for all categories. YLL were not  accounted for due 
to the lack of mortality data for the disease.  
Simulations were performed using SAS Software, version 9.4 
 
3.4 Results 
 
A total of 446 surgical CE cases were reported between 2006-2016 in Mongolia. The 
mean age of cases was 28.3 (95%CI 26.4-30.3). The percentages of males and females 
were 44% and 56%, respectively. For the non-surgical cases, a total of 185 cases were 
detected with CE in the abdominal organs from 8 provinces during 2016. The mean 
age of non-surgical cases was 57.9 (95%CI 55.3-60.6). The percentages of males and 
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females were 30% and 70%, respectively. The estimated number of diagnosed 
(surgical and non-surgical) cases for 2018 is 476.4 (95%CI 386.8-569.7) and of total cases 
is 1810.3 (95%CI 1463.3-2171.8) (Table 1). The incidence (per 100’000 person years) 
based on the estimated number is 2.2 (95%CI 1.8-2.7), for surgical cases, 15.9 (95%CI 
12.9-19.0), for diagnosed cases, and 60.3 (95%CI 48.8-72.4) for diagnosed and  
undiagnosed cases.  
A total of 65 surgical cases agreed to participate in the cost interview. The 
median age of patients interviewed was 37 (IQR: 16 to 53). 75% of the patients agreed 
to participate were hospitalized during 2013-2016. The percentage of female and male 
were 49% and 51%, respectively. 83% were from rural areas. The percentages of 
herder, student, retired, employed, unemployed and disabled patients were 24.9%, 
24.9%, 16.9%, 16.9%, 12.3% and 4.6%, respectively. The average monthly family 
income was US$ 150-300 for 63%, below US$ 150 for 18.5% and above US$ 300 for 
18.5%. 32% of the families had a member who was employed. 30% of the patients, 
family income source was from welfare support (i.e child support, pensions). The 
percentage of patients accompanied by the caretaker was 70% (Table S2, Table S3). 
52% of the patients received a bank loan (i.e salary, retirement, herders loan) for health 
care seeking for CE surgery.  
 
Table 1.Predicted number of cases of CE, for  2018 
Categories Cases Incidence* 
mean 95% CI mean 95% CI 
Surgical cases 67.3 55.0-80.1 2.2 1.8-2.7 
Non-surgical cases 409.1 321.4-499.8 13.6 10.7-16.6 
Undiagnosed cases 1334 1076-1604 44.5 35.8-53.5 
Total diagnosed cases 476.4 386.8-569.7 15.9 12.9-19.0 
Total cases* 1810 1463-2172 60.3 48.8-72.4 
* number of cases per 100,000 person years 
 
Estimated individual cost due to CE. The average estimated cost per surgical case is 
US$ 3020 (95%CI US$ 2650-3420) and for non-surgical cases it is US$ 350 (95%CI US$ 
290-400). The estimated direct medical public cost for surgical patients is US$270 
(95%CI 240 - 310) and for non-surgical patients US$80 (95%CI US$50-110). The 
estimated direct medical private cost for surgical patients is US$910 (95%CI US$700-
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1140) and for non-surgical patients US$ 50 (95%CI US$ 30-70). The estimated direct 
non-medical cost for surgical patients is US$ 1090 (95%CI US$ 860-1350) and for non-
surgical patients US$ 160 (95%CI US$ 120-210). Estimated income loss for surgical 
patients is US$ 580 (95%CI US$ 460-700) and for non-surgical cases US$ 80 (95%CI 
US$ 70-90). 
 
Estimated total cost in human. The estimated total cost due to human CE was US$ 
2’741’580 (95%CI US$ 2’238’900- 3’266’280), when accounting for the undiagnosed 
cases and for productivity loss. The respective estimate was US$ 346’130 (95%CI US$ 
284’860- 413’240) when accounting only for the diagnosed cases and disregarding 
productivity loss.  Among the total cost without productivity loss,  39%, were 
attributed to direct medical costs,  40% to direct non-medical costs, and 20% to indirect 
costs. Total estimated cost of surgical cases was US$ 203’600 (95%CI US$ 159’680- 
251’890). Of the total cost for surgery, 39% were attributed to direct non-medical cost, 
30% to direct medical cost covered by patients and 9% to direct medical cost covered 
by insurance and 22% to indirect costs. Thus, 91% of cost was covered by the patients 
for receiving the CE surgery.  Loan interest payments accounted for about 5% of these 
costs.  The total cost for non-surgical cases was estimated to be US$ 142`770 (95%CI 
US$ 106’200-183’670), and 70% of it was attributed to direct medical costs, 15% to 
direct non-medical costs and 15% to indirect costs.  
The estimated productivity loss including undiagnosed cases was US$ 
2’395’460 (95%CI US$ 1’935’440-2’875’820). Of the total cost, 87% was attributed to the 
productivity loss. Beside productivity loss, the item with the highest contribution was 
chemotherapy, assuming non-surgical cases to be treated with albendazole as well. 
Among the parameters in the direct medical cost, the informal fee for surgeon is the 
second most influential. The most influential item for the direct non-medical cost is 
purchase of food during the stay in Ulaanbaatar city. For the indirect cost, monthly 
income of the patient has high influence (Figure 1).  
 
DALY estimates. The total estimated DALY for diagnosed cases are 11`461 (95%CI 
9`264-13`752) when including the undiagnosed cases. The corresponding estimates are 
, 3017 (95%CI 2449-3607) for diagnosed cases,  426 (95%CI 348-507) for surgical cases 
and 2590 (95%CI 2033-2588) for nonsurgical cases.   
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Table 2. The cost of human CE in Mongolia.  
Categories cost (USD*) Mean LCL UCL 
Surgical       
Direct medical cost (public) $18,530 $14,490 $22,970 
Direct medical cost (private) $61,650 $43,910 $81,830 
Direct non-medical cost $73,250 $53,540 $96,440 
Indirect cost** $38,560 $28,730 $49,750 
Loan cost $11,360 $7,330 $16,250 
Total cost (surgical) $203,360 $159,680 $251,890 
Non-surgical cases       
Direct medical cost (public) $33,220 $20,690 $47,610 
Direct medical cost (private) $67,760 $46,090 $92,840 
Direct non-medical cost $21,660 $12,930 $31,620 
Indirect cost** $20,130 $15,220 $25,540 
Total cost (non-surgical) $142,770 $106,200 $183,670 
Total medical cost (public) $51,750 $36,970 $68,440 
Total medical cost (private) $83,310 $63,010 $106,000 
Total non-medical cost $141,010 $110,370 $175,340 
Total indirect cost** $70,060 $55,990 $85,730 
Total societal medical cost** $346,130 $284,860 $413,240 
Total productivity loss $2,395,460 $1,934,440 $2,875,820 
Total indirect cost*** $2,465,510 $1,997,560 $2,953,300 
Total cost*** $2,741,580 $2,238,900 $3,266,280 
*- 1USD= 2000 Mongolian currency (Tugrik), 2016 
**- Without productivity loss 
***- Including productivity loss for all cases (diagnosed + undiagnosed). 
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Figure 1. Contribution of different cost items to the total cost  
 
3.5 Discussion 
 
This is the first estimation of the societal cost of human CE in Mongolia. CE is a 
neglected disease that affects the marginalized population. The disease causes a 
significant amount of loss to society and household economy. Our results inform 
decision makers to further develop a strategy to control the disease and prevent the 
future cost of CE. 
The economic loss due to human CE was US$ 2.7 million when accounting the 
productivity loss, which is equal to 0.024% of the Gross Domestic Product (GDP) of 
Mongolia. This estimate is slightly smaller than previous estimates in other CE 
endemic countries which ranged between 0.03-1.5% of GDP (Torgerson et al., 2000; 
Torgerson et al., 2001; Bingham et al., 2016). One reason may be that the production 
loss of animals could not be accounted for due to an absence of prevalence data. In 
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our study, almost 87% of total cost is attributed to the human productivity loss, which 
is similar to a study  in Argentina 77%(Bingham et al., 2016). In the most extreme case, 
a study in Spain calculated a loss of 133 million when including  lost productivity and 
only 0.9 million otherwise (Benner et al., 2010).   
The impact on the household economies is high for surgical cases where an 
estimated 76% of the direct cost is paid by the patients. A recent report from Mongolia 
found that 70% of the medical cost for health care in chronic disease was from out-of-
pocket and that this proportion increased to 80% for diagnostics (Dugee et al., 2018). 
Our study provides an example of a catastrophic-health-care-expenditure exceeding 
the resources of households, which is a major issue in Mongolia and discussed 
extensively in the public health reports currently (Dugee et al., 2017). According to 
our estimates, only 10% percent of costs among surgical cases is covered by the public 
health system. The remaining 90% (US$ 2575) correspond to 70% of the average 
annual family income. This explains why about half of the patients interviewed 
reported that they had to take a bank loan while seeking health care. As CE is mostly 
affecting marginalized populations in rural areas, it contributes to the poverty of 
Mongolia. 
The cost of albendazole had the highest impact on total cost (without 
productivity loss) (Figure 1). However, in current practice, albendazole is mainly 
administered to surgical cases so that surgery is the main treatment option at present, 
offered only by  tertiary hospitals. There are two main factors impeding the 
implementation of albendazole treatment, 1) the lack of a diagnostic algorithm of CE 
bringing uncertainty to choose the right management, and 2) the high price and 
limited supply of albendazole. Similar challenges are present in other low-middle-
income countries (Bold et al.; Junghanss et al., 2008; Del Carpio et al., 2012; Tamarozzi 
et al., 2014; Becker et al., 2016). According to our survey, the price of one pill of 
albendazole equals approximately 20% of the patients’ daily income. Also, the 
availability of albendazole shows large regional differences.  
The total case number including undiagnosed cases per year is 1810 which are 
60 cases per 100’000 while diagnosed cases are 15 per 100’000. The estimation of the 
undiagnosed cases was the most challenging part. One strong reason to believe that 
there are many undiagnosed cases is the high percentage of young children who are 
hospitalized for CE surgery. On the other hand, among non-surgical cases, older 
patients were over-represented. While some of the infected persons may be 
asymptomatic or have only slight symptoms, others may prefer not to seek health care 
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in order to prevent income and workday loss. One solution would be to invest in 
percutaneous treatment for CE, which requires shorter hospital stays than open 
surgery (Junghanss et al., 2008; Brunetti et al., 2010). Moreover, there are promising 
and implementable tools of telemedicine supporting the  decision of patients’ referral. 
There is a great need to conduct community-based surveys to understand the true 
burden of the disease across all age groups.  
The total estimated DALY when including the undiagnosed cases was 11461 as 
opposed to 3017 for the diagnosed cases only. The studies before 2015 used mainly 
disability weights (DW’s) of liver cancer which are not comparable (Budke et al., 2006; 
Wang et al., 2012). The most recent studies used different DW’s depending on the 
clinical severity (Counotte et al., 2016). In Kyrgyzstan, for untreated and undiagnosed 
cases a DW of 0.012 (for hepatic), 0.015 (for pulmonary) and 0.054 (for CNS) was given. 
For our study, we assumed a lifelong duration of the disease and a DW of 0.123 for all 
cases, assuming that patients with latent diseases or not seeking health care may suffer 
the same level of disability. Further studies are needed to estimate the DW’s and 
durations for each CE stage.  
We could not estimate YLL due to the unavailability of mortality data for CE. 
The hospital data in other countries reported fatality rate of 1-2% due to 
echinococcosis, mostly to surgical complication (Herrador et al., 2016). Number of 
death due to echinococcosis in Mongolia would be 5-10 if the percentage from 
previous study was employed. But fatality rate of people going under treatment can 
be dependent from hospital performance and surgical capacity. We assumed that 
capacity of surgery and hospital situation in Mongolia is different than other countries 
mainly due to its low resource. Thus, the mortality estimate from previous studies 
were not incorporated in our calculation.   
An important limitation of the study is that the cost associated with animal loss 
due to CE is not accounted for. Studies in other countries having considered  livestock 
production loss quantified the  percentage of total cost associated with livestock loss 
to range between  10 and 88% (Moro et al., 2011; Carabin et al., 2014; Singh et al., 2014; 
Bingham et al., 2016). In Mongolia, livestock agriculture is an important economic 
source. However, the lack of public slaughterhouses in the country makes it difficult 
to collect data on animal disease. The inclusion of livestock cost must be one of the 
next steps. 
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This study is based on primary data on surgical and non-surgical cases of CE 
and the related cost. The statistical simulations used should provide a valid estimates 
within the ranges of uncertainty.  
Our result highlights the need for cost-effective control action for CE to prevent 
high societal cost and burden. Currently, there is no control, and preventive action is 
taking place in Mongolia regarding CE. There are many preventive strategies 
potential to be implemented including health education, dog deworming, 
slaughterhouse improvement and the sheep vaccine which is currently under trial in 
Argentina and China (Torgerson and Heath, 2003; Gauci et al., 2005; Larrieu et al., 
2013). The sheep vaccination combined with dog deworming is estimated to be the 
most cost-effective on a global scale (Torgerson and Heath, 2003). However, the 
challenge remains in understanding the transmission dynamics of CE in Mongolia 
due to lack of information in the animal population. 
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3.7 Supplementary material 
 
Table S1. Summary statistics of each parameters used for cost estimation  
(US$ 1=2000 MNT-Mongolia currency, Tugrik) 
  Categories Mean SE 
Surgical cases     
1 Direct medical public cost      
1.1 Unit cost of laboratory test  MNT33,947   MNT2,522  
1.2 No. of laboratory tests 2.0  0.3  
1.3 Unit cost ultrasound  MNT21,089   MNT861  
1.4 No. of ultrasound 3.1  1.0  
1.5 Unit cost of X-ray  MNT15,838   MNT411  
1.6 No. of X-ray 1.4  0.3  
1.7 Unit cost for hospital stay (secondary)  MNT10,000    
1.8 No. of hospital stay (secondary)  7.0    
1.9 Number of hospitalization (secondary) 1.8  0.1  
1.10 Unit cost for hospital stay (tertiary)  MNT15,000    
1.11 No. of hospital stay (tertiary) 14.8  0.8  
1.12 Number of hospitalization (tertiary) 1.1  0.1  
2 Direct medical private cost     
2.1 Unit cost of CT  MNT322,057   MNT6,490  
2.2 No. of CT  1.0  0.0  
2.3 Additional diagnostics  MNT105,625   MNT32,437  
2.4 Unit cost of albendazole  MNT4,304   MNT214  
2.5 No. of days of albendazole treatment 73.9  8.9  
2.6 Cost Supportive drugs/materials  MNT94,286   MNT16,043  
2.7 Cost Informal fee for surgeon   MNT572,029   MNT153,494  
2.8 Cost Informal fee for nurse  MNT211,429   MNT30,034  
2.9 Cost Supportive treatment  MNT263,804   MNT82,783  
3 Non medical out-of-pocket cost (Surgical)     
3.1 Unit cost of transport (secondary)  MNT15,539   MNT2,892  
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3.2 No. of hospitalization (secondary) 1.8  0.1  
3.3 Unit cost of transport (tertiary)  MNT77,246   MNT9,913  
3.4 No. of hospitalization (tertiary) 1.1  0.1  
3.5 Unit cost of local transport (city)  MNT5,163   MNT316  
3.6 No. of local transport (city) 3.7  0.2  
3.7 Unit meal cost (UB stay)  MNT10,065   MNT1,356  
3.8 No. of days of stay in UB before surgery 29.6  3.5  
3.9 No. of days of stay in UB after surgery  13.9  1.4  
3.10 Unit cost of accommodation   MNT15,000    
3.11 Unit cost for meal (in hospital)  MNT8,484   MNT997  
3.12 No. of hospital stay 14.8  0.8  
4 Indirect cost     
4.1 Unit income   MNT19,923   MNT1,158  
4.2 No. of stay in UB (patient) 35.9  4.2  
4.3 Unit income of caregiver  MNT19,418   MNT2,102  
4.4 No. of stay in UB (caregiver) 28.5  2.9  
4.5 People recruited for the farm 175000 35355.34 
Non-surgical cases 
  
Direct medical public cost     
5 
5.1 Unit cost of ultrasound  MNT21,089   MNT861  
5.2 No. of ultrasounds 3.1  1.0  
5.3 Unit cost X-ray  MNT15,838   MNT411  
5.4 No. of X-ray 1.4  0.3  
5.5 Unit cost of laboratory test  MNT33,947   MNT2,522  
5.6 No. of laboratory tests 2.0  0.3  
6 Direct medical private cost     
6.1 Unit cost of albendazole   MNT4,304   MNT214  
6.2 No. of days albendazole taken 73.9  8.9  
7 Direct non-medical cost     
7.1 Unit cost of transport (secondary)  MNT15,539   MNT2,892  
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7.2 No. of hospitalization (secondary) 5.0  1.1  
7.3 Unit cost of transport (primary)  MNT3,594   MNT872  
7.4 No. of hospitalization (primary) 10.0    
8 Indirect cost     
8.1 Unit income (patient)  MNT19,923   MNT1,158  
8.2 No. of days of absent from work (patient) 5.0  1.1  
8.3 Unit income (caregiver)  MNT19,418   MNT2,102  
8.4 No. of days of absent from work (caregiver) 5.0  1.1  
 
 
Table S2. Background information of the participants (surgical 
patients) 
  n=65 % 
Age     
5--15 15 23.10% 
16-59 40 61.50% 
60< 10 15.40% 
Sex     
Female 32 49.20% 
Male 33 50.80% 
Occupation     
Student 16 24.60% 
Herder 16 24.60% 
Retired 11 16.90% 
Employed 11 16.90% 
Unemployed 8 12.30% 
Disability 3 4.60% 
Education     
Primary 6 9.20% 
Middle school 11 16.90% 
High school 25 38.50% 
University 5 7.70% 
Children under 16 16 24.60% 
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NA 2 3.10% 
Hospital of admission     
First National Hospital 40 61.50% 
Childrens` Hospital 17 26.20% 
Third National Hospital 8 12.30% 
Most recent CE surgery     
2016 4 6.20% 
2015 20 30.80% 
2014 15 23.10% 
2013 10 15.40% 
2012 8 12.30% 
2011 5 7.70% 
2010 3 4.50% 
 
Table S3. Socio-Economic-Status of patients`family 
SES background n=65 % 
Number of members in family     
1--2 9 13.80% 
3--5 39 60.00% 
6< 17 26.20% 
Number of children (under 16 yr old)     
1--2 32 49.20% 
3--5 21 32.30% 
0 12 18.50% 
Number of elderly (over 60 yr old)     
1 17 26.20% 
2 5 7.70% 
0 43 66.20% 
Number of people working     
1 13 20.00% 
2 7 10.80% 
3 1 1.50% 
!"
	 	
0 44 67.70% 
Number of herders in the family     
1 6 9.20% 
2 20 30.80% 
0 39 60.00% 
Number of people with disability     
1 5 7.70% 
2 1 1.50% 
0 59 90.80% 
Income     
<US$ 150 12 18.50% 
US$ 150 - US$ 300 41 63.10% 
> US$ 300 12 18.50% 
Income source from welfare     
30% 22 33.80% 
100% 19 29.20% 
10% 12 18.50% 
60% 8 12.30% 
0% 4 6.20% 
Caretaker of the patient     
Parent 20 30.80% 
Spouse 12 18.50% 
Children 8 12.30% 
Siblings 6 9.20% 
NA 19 29.20% 
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Abstract
Cystic echinococcosis (CE), the parasitic disease caused by the larval stage of Echinococcus granulosus sensu lato (s.l.), is a global
public health problem. InMongolia, despite wide distribution of human CE, not enough information is available on the prevalence and
molecular characterization of CE in livestock and its zoonotic linkage with human cases.We investigated the distribution of human CE
cases and livestock population using statistical models to get insight into the zoonotic linkage. The incidence of human CE cases
increased by a factor of 1.71 for one interquartile range increment in the density of the camel population. No significant associationwas
observed with other livestock species. The samples collected from 96 camels and 15 goats in an endemic region showed a CE
prevalence of 19.7% and 6.7%, respectively. All livestock CEwereE. granulosus s.l. G6/G7 species of the E. granulosus s.l. complex.
The genetic diversity was investigated using the haplotype network based on full cox1 gene analysis of the samples collected from
livestock CE and nucleotide sequences previously reported from human CE and wild canids infection in Mongolia. Four haplotypes
were identified within the livestock samples, two of which had not been previously reported. A common haplotype was identified
among humans, camels, goats, and a wolf, all of which were within the same geographical area. Amixed infection ofE. granulosus s.l.
G6/G7 with different haplotypes in the intermediate host was identified. To the best of our knowledge, this is the most comprehensive
description of the current epidemiological situation of CE in Mongolia with substantial evidence that camels might be the main
intermediate host of E. granulosus s.l. G6/G7 in Mongolia. Moreover, our result presents the first report in the country to provide
insight into the prevalence of E. granulosus s.l. G6/G7 in livestock.
Keywords Echinococcus granulosus s.l.G6/G7 . Cystic echinococcosis . Camel . Goat . Mongolia
Introduction
Cystic echinococcosis (CE) is the parasitic disease caused by
the larval stage of Echinococcus granulosus sensu lato (s.l.).
The disease burden worldwide is estimated to be 184,000
disability-adjusted life years (DALYs), most of which are
from pastoral communities due to their close contact with host
animals (Budke et al. 2004; Torgerson et al. 2015). The main
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definitive host of the parasite is the dog when other canids as
wolves but also in a lesser extent some felids in Africa may
harbor the worms in their intestines (Romig et al. 2017). A
wide range of livestock species including sheep, cattle, goats,
camels, and pigs may act as intermediate hosts with the pres-
ence of hydatid cysts in the liver and/or lungs (Nakao et al.
2013a; Romig et al. 2015).
InMongolia, nomadic pastoral farmersmake up approximate-
ly one-third of the population raising more than 60 million live-
stock including sheep, goats, cattle, and camels, all of which are
potential intermediate hosts (NSO 2017; Romig et al. 2017).
Dogs are expected to be the predominant definitive host since
all farmer family has more than one watch-dog (Gurbadam et al.
2010). Historically, CE prevalence was high in all parts of the
country since the early twentieth century (Jezek et al. 1973; Jezek
et al. 1971), but with an intensive control program supported by
the former Soviet Union, the number of surgical cases decreased
from 13% in 1946 to 2% in 1988 in the state hospital
(Davaatseren et al. 1995; Ito and Budke 2015). The economic
collapse in the 1990s followed by the privatization of veterinary
sector hugely influenced the decline of control and prevention of
zoonotic diseases in Mongolia (Ebright et al. 2003; Torgerson
et al. 2006). In parallel, unregulated private slaughtering practices
dramatically increased in rural areas of Mongolia (Gurbadam
et al. 2010; McFadden et al. 2016). In slaughterhouses, infected
offal is often available and consumed by free-roaming dogs,
which is a major factor in perpetuating the CE transmission cycle
(Craig et al. 2017). Currently, human CE cases are reported as
aggregated data with other surgical diseases; therefore, official
data is not available.More recent retrospective studies investigat-
ing surgical CE cases, however, reveal that almost half of all
cases were children less than 15 years of age, strongly suggesting
active transmission in the animal population (Bold et al. 2018).
E. granulosus s.l. is defined as a complex of five cryptic
species: E. granulosus sensu stricto (s.s.), Echinococcus felidis
(exclusively in Africa), Echinococcus equinus, Echinococcus
ortleppi, and Echinococcus canadensis (Nakao et al. 2013a;
Nakao et al. 2013b; Romig et al. 2017; Romig et al. 2015).
The taxonomy concerning the latter species is still disputed,
as it groups the previous four genotypes and strains: G6 (camel
strain), G7 (pig strain), and the two cervid strains G8 and G10.
Genetic analyses from mitochondrial genes and some nuclear
genes have grouped genotypes G6 and G7 together in the same
clade, with differentiation from the other two genotypes (Addy
et al. 2017b; Yanagida et al. 2017) potentially regarding
these genotypes as two different species (Laurimae et al.
2018a). Thus, the genotypes G6/G7 of E. canadensis will be
designed here as E. granulosus s.l. G6/G7. Worldwide, most
human cases (99.5%) are caused by E. granulosus s.s. and
E. granulosus s.l. G6/G7 (Alvarez Rojas et al. 2014), while
the species found in human CE cases in Mongolia are
E. granulosus s.s. and E. canadensis (G6/G7 and G10) (Ito
et al. 2014; Jabbar et al. 2011; Shirmen et al. 2018). One of
the few investigations on the definitive host of Echinococcus
spp. in Mongolia found wolves infected with E. canadensis
(G6/G7 and G10) from southern region through wild animal
carcass surveys (Ito et al. 2013). There is, however, very limited
information for the livestock populations due to the lack of
public slaughterhouses and animal surveillance tools in the
country (Chinchuluun et al. 2018; Deplazes et al. 2017). To
date, there is not enough information on the molecular charac-
terization of Echinococcus species causing CE in livestock
(Yanagida et al. 2017). As a result, the transmission cycle of
CE inMongolia is largely unknown despite wide distribution of
CE in the country. In our study, we provide the first investiga-
tion into the zoonotic linkage of CE between humans and ani-
mals in Mongolia using epidemiological and molecular
approach.
Materials and methods
Data collection of human and animal population
Mongolia has 331 “soums” (smaller administrative unit of
province) in 21 provinces and 1 city, Ulaanbaatar. Data on
the human population was collected from the National
Statistical Office (NSO) for adjustment of CE cases. We col-
lected population data on sheep, camels, goats, and cattle as
potential intermediate hosts of CE from the NSO (NSO 2017;
Romig et al. 2017). Data were aggregated by livestock species
by soum and year with a unit of 1000 heads. For the statistical
analysis, the population density of each livestock species
(expressed as number of animals per square km) was used as
the exposure measure.
Data collection of human cases of CE
Data regarding patients recorded with the diagnosis of CE
(ICD code 67.1–67.9) between 2006 and 2016 were extracted
from the digital archive of Health Development Center of
MoH. We collected information regarding age, sex, registra-
tion number, residential province, admission date, hospital
name, and received treatment modalities. The analysis was
restricted to surgical cases from tertiary-level hospitals, which
represent approximately 98% of all surgical CE cases in
Mongolia. Human cases of CE subsection were anonymized.
The data was aggregated by year and province for further
statistical analysis.
Data collection of molecular genetic information
of human CE and definitive host
Forty-three CE cases were confirmed previously by histopa-
thology at the National Center of Pathology in Ulaanbaatar
(Ito et al. 2014). Among them, 29 cases including 17 children
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were caused by E. granulosus s.l. G6/G7. Infections by
E. granulosus s.l. G6/G7 were also diagnosed previously in
one wolf each from both Gobi-Altai and Zavkhan provinces,
which are in the southwestern part of the country (Ito et al.
2013). As the entire mitochondrial cytochrome c oxidase sub-
unit 1 (cox1) was available in GenBank for these human and
wolf cases, the corresponding haplotypes were included in the
present study in order to obtain a more complete overview of
the genetic diversity of E. granulosus s.l. G6/G7 in Mongolia.
Biological sample collection from intermediate host
Animal samples from camels and goats were collected from
Khurmen and Khankhongor soums of Omnogobi province,
which has distance of 330 km from each other. The animals
were being processed as part of the normal work of the slaugh-
terhouse. Omnogobi province is located in the Gobi Desert
toward the southern part of the country, with a climate ranging
from − 20 to − 30 °C in winter and + 30 to + 38 °C in summer.
The province has approximately 60,000 people in an area
measuring 165,000 km2. The majority of this area is used
for nomadic pastoral farming. The province has 2%, 6%,
0.5%, and 30% of the total sheep, goat, cattle, and camel
populations in the country, respectively (Appendix 2) (NSO
2017). Omnogobi was selected for the sampling in this re-
search because according to the previous report, it had the
highest number of surgical CE cases (Bold et al. 2018).
Samples were collected from a site in Khankhongor soum
and three sites in Khurmen soum in December 2016.
November to December is the winter meat preparation period
inMongolia. The camels and goats included in this study were
to be used as winter meat storage for the local military. A total
of 96 camels and 15 goats from 9 farms were slaughtered
under the supervision of a local veterinarian for the meat prep-
aration in winter. All organs of the pleural and abdominal
cavities were inspected to determine the presence of hydatid
cysts.When cystic lesions were detected, the cyst contents and
wall were kept in a tube containing 96% alcohol. Sampling
site, animal species, and organ affected were recorded for each
sample. The samples were transported to the central laboratory
in a portable freezer where it was stored at − 20 °C. After
thawing, cyst material was incised with a scalpel. The internal
layer of the cyst was applied to an FTA® card for 20 s to
impregnate the paper with parasite cells (Boue et al. 2017).
The FTA® cards were dried at room temperature for 24 h
before shipment to the laboratory (Anses, Malzéville,
France) for genetic analysis. One to four hydatid cysts per
animal was sampled using the FTA card (Appendix 1).
Statistical analysis
Quantitative variables were described using mean and inter-
quartile range (IQR) and qualitative variables using absolute
and relative frequencies. To investigate the link between hu-
man CE cases and livestock population, we developed multi-
variable mixed negative binomial regression models for the
total number of cases and the number of cases among children
under 15 years of age per province and year. As sheep, goats,
cattle, and camels are all potential intermediate hosts, their
population densities by province and year were included as
predictor variables in the full model. The human population
was used as the offset variable to adjust for differences in
population size. Random intercepts at the level of provinces
were also included in the models to adjust for potential geo-
graphic clustering. A potential effect of hospital accessibility
on observed counts of CE cases was assessed using an indi-
cator variable for provinces along the railroad. Significant
relations were illustrated by a map showing mean surgical
incidence at the province level and animal population density
at the “soum” level between 2006 and 2016. All analyses and
maps were done using the statistical package R v 3.4.0.
Molecular analyses and haplotype network
DNA extraction was performed as previously described using
approximately 1 cm square of each impregnated FTA card
(Boue et al. 2017). After lysis, the iPrep Charge Switch
gDNATissue kit (Invitrogen)was usedwith the iPrep purification
instrument to extract DNA. The entire cox1 gene (1608 bp) was
sequenced with a nested PCR using two pairs of primers to
amplify the gene in one piece (Addy et al. 2017a). The nucleotide
sequences were analyzed and aligned using the Vector NTI soft-
ware program (Invitrogen). A network of the cox1 haplotypes
was drawn using statistical parsimony with TCS 1.2 software
(Clement et al. 2000) and online tcsBU software (Murias dos
Santos et al. 2016) to highlight the diversity and relationships
among the different haplotypes. The E. granulosus s.l. G6/G7
haplotypes of the complete cox1 gene from the humans (n = 29)
and wolves (n = 2) identified in Mongolia were added to the
haplotype network (Ito et al. 2013; Ito et al. 2014). In order to
increase the number of sequences in the haplotype network and
to place the Mongolian sequences in a broader geographical
context, sequences from 94 samples from 6 intermediate host
species originating from 15 different countries obtained by
Laurimae et al. (2018b) were added.
Results
Statistical analysis
A total of 446 surgical cases were reported from 2006 to 2016
in Mongolia. The median age of CE cases was 23.0 years
(IQR = 10.0–44.7). The percentages of males and females
were 44% and 56%, respectively (p value = 0.01). The inci-
dence of surgical cases was 1.4 per 100,000 person years. The
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median densities of livestock for sheep, goats, cattle, and
camels were 15.3 (IQR 9.36–24.48), 15.0 (IQR 10.76 -
19.92), 1.96 (IQR 1.00–3.76), and 0.10 (IQR 0.04–0.23) per
1 km2, respectively. Human CE cases were significantly relat-
ed to camel density in the model with all animal species
(Table 1). CE incidence across all ages increased by a factor
of 1.71 (1.42–2.04) for an IQR increment in camel density
(i.e., 1 camel per 1 km2) and the respective increase was
2.08 (1.66–2.61), among children under 15 years of age.
There were no significant associations between human CE
cases and other animal species densities in the first model. In
the secondmodel with an indicator variable for provinces with
railroad stations, the incidence rate ratio associated with camel
density was 1.78 (1.55–2.05) and the negative association
with cattle density became statistically significant. Living
close to a railroad increased human CE incidence significantly
by a factor of 1.6 (1.2–2.1) compared to living farther away
from railroads. In provinces without railroad connections, the
incidence rate ratio associated with camel density increased to
1.88 (1.61–2.20) while no significant associations were ob-
served with other animal densities.
We also estimated and plottedmarginal CE incidence rate as a
function of camel population density. The positive association
between camel density and human CE cases is illustrated in
Fig. 1.
The highest incidences of CE were reported from
southern provinces including Omnogobi, Dornogobi,
Dundgobi, and Bayankhongor with 7, 3, 4, and 3 cases
per 100,000 person years, respectively (Fig. 2). Northern
provinces including Arkhangai, Orkhon (a former city),
Dornod, and Ulaanbaatar city had the lowest case num-
bers per 100,000 person years. In parallel, camel popula-
tion densities were also higher in southern as compared to
northern provinces. The highest CE incidence and the
highest camel population density were both observed in
the province of Omnogobi.
Molecular genetic analysis
The species E. granulosus s.l. G6/G7 was identified in all the 33
FTA samples isolated from 19 camels and 1 goat. The CE prev-
alence was estimated as 19.7% (CI95% 12.4–29.2%) in camels
and 6.7% (CI95% 1.7–32.0%) in goats. The nucleic sequence of
the entire cox1 genewas obtained from32 samples as only partial
results were obtained for one camel sample despite successive
assays. Four haplotypes (numbered 1 to 4) were identified with
one to four point-mutations (only substitutions) within each other
(Appendix 1). Haplotypes 1 and 3 were reported previously in
GenBank from the human samples collected in Mongolia (Ito
et al. 2014). The haplotypes 2 and 4 had not been reported before.
The haplotype 2 is identified as 99% (1607/1608 bp) with hap-
lotypes EcMGL6 from Mongolia and Ec01 from African coun-
tries, while haplotype 4 is identified as 99% (1607/1608 bp) with
EcMGL15 from Mongolia (Addy et al. 2017b; Ito et al. 2014).
As identified in 9 of the 20 infected animals, haplotypes 1 and 2
were the most represented ones, whereas haplotypes 3 and 4
were identified in only three and one animal(s), respectively.
The presence of two different haplotypes was observed in two
camels with presence of haplotypes 1 and 2 in both cases. The
haplotype network reveals a double star-like configuration
(Fig. 3), where haplotypes designed as genotype G6 are around
haplotype 1 when the haplotypes designed as G7 are hap3, hap4,
haplotype 3 and haplotype 4 and those around them.Haplotype 1
identified in this study was previously described in the same
species of intermediate hosts (camels, goats, human) from Iran,
Argentina, Kenya, Sudan, and Mauritania but also including the
haplotype Gmon from a human case of CE in Mongolia. No
other correspondence with haplotypes from Laurimae et al.
(2018b) was found with haplotypes 2 to 4 described in this study
as well as for the haplotypes from human CE cases described by
Ito et al. (2014). Concerning onlyMongolia, haplotype 1 appears
Table 1 Model prediction of human CE cases and livestock density
population
Covariates Estimatea 95%LCL 95%UCL P value
Camel density 1.71 1.42 2.04 < 0.0 01
Sheep density 1.13 0.71 1.8 0.61
Cattle density 0.91 0.8 1.03 0.14
Goat density 0.91 0.7 1.18 0.46
Covariates Estimatea 95%LCL 95%UCL P value
Camel density 1.71 1.42 2.04 < 0.0 01
Sheep density 1.13 0.71 1.8 0.61
Cattle density 0.91 0.8 1.03 0.14
Goat density 0.91 0.7 1.18 0.46
LCL lower confidence level, UCL upper confidence level
a The estimate for the IQR increment in the density of the respective
animal population
Fig. 1 The predicted incidence of surgical CE cases in humans by camel
population density, 2006–2016 (number of camels per 1 km2)
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to be predominant in Mongolia with identification in camels and
humans (corresponding to haplotype EcMGL2 (Ito et al. 2014)),
when one of the two wolves as definitive hosts also harbors this
haplotype. There are generally few mutations between the
different haplotypes fromMongolia (with a maximum of seven),
independent of the species and the origin areas of the samples.
The haplotype 2 was the most prevalent in camels, along with
haplotype 1 which was also found in humans. Haplotype 3 was
Fig. 3 Haplotype network is based on the full cox1 gene (1608 bp) using
statistical parsimony of the E. canadensis G6/G7 samples from camels
and goats (this study), humans andwolves (Ito et al. 2013; Ito et al. 2014),
and 94 samples from 15 countries described by Laurimae et al. 2018b.
The worldwide collection composed by G6 samples (n = 27) originated
fromAfrica (Sudan, n = 14; Kenya, n = 3;Mauritania, n = 2), Middle East
(Iran, n = 4), Asia (Mongolia, n = 1), and South America (Argentina, n =
3). Genotype G7 samples (n = 67) originated from Europe (Spain, n = 1;
France, n = 27; Italy, n = 2; Serbia, n = 1; Romania, n = 2; Ukraine, n = 2;
Poland, n = 5; Lithuania, n = 1), Central America (Mexico, n = 10), and
South America (Argentina, n = 16). For camels, only one sample per
animal was included with the exception of two camels, which harbored
two haplotypes. So, one of both haplotypes was retained. Size of the circle
is proportional to the number of samples. The smaller white points
represent each mutational steps/hypothetical haplotypes
Fig. 2 Geographical distribution of camel density (in number of camels
per 1 km2) and incidence (in number of cases per 100,000 person years).
The average camel density between 2006 and 2016 is plotted as base-
layer for each soum (gray choropleth). The mean annual incidence of
surgical CE cases per 100,000 between 2006 and 2016 is plotted for
each province (black circle). Abbreviations of provinces: BO Bayan-
Olgii, UV Uvs, HD Khovd, DZ Zavkhan, GA Gobi-Altai, BH
Bayankhongor, OH Ovorkhangai, AR Arkhangai, HG Khubsgul, BU
Bulgan, DA Darkhan, SL Selenge, ER Orkhon, UB Ulaanbaatar, DU
Dundgobi, OG Omnogobi, TO Tov, DG Dornogobi, HN Khentii, DD
Dornod, GS Gobisumber, SB Sukhbaatar
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found in camels and in one human case (EcMGL15). The hap-
lotype 4 was identified only in one camel, but it differs from
haplotype 3 by only one mutation. In the southern Omnogobi
province, where the camels originated, haplotype 1 was identi-
fied in camels, goat, and humans (Fig. 4).
Discussion
To the best of our knowledge, the current research provides
the most comprehensive description of the current epidemio-
logical situation of both human and livestock CE inMongolia.
An important finding of our study is that we identified the
common haplotype among E. granulosus s.l. G6/G7 in
humans, camels, goats, and a wolf in the same region. This
haplotype also corresponds to the main haplotype for G6 iden-
tified worldwide by Laurimae et al. (2018b). Our results pro-
vide substantial evidence indicating that camels are the main
intermediate host of the E. granulosus s.l. G6/G7 species of
the E. granulosus s.l. complex in Mongolia. Moreover, this is
the first report from Mongolia that provides insight into the
prevalence of E. granulosus s.l. G6/G7 in goats and camels,
with confirmation of molecular species diagnostic, though the
sample size and number of sampling locations needs to be
increased. Interestingly, the haplotypes 3 and 4 appear to be
more designed as G7 rather than G6 which was more expect-
ed. It highlights the interest to analyze additional genes or
even the entire mitochondrial genomes as complete cox1 gene
has proved to potentially not correctly differentiate between
G6 and G7 genotypes (Laurimae et al. 2018b). In this context,
it will be relevant to obtain more genetic information about
haplotypes found inMongolia when the only one sample from
this country in the study of Laurimae et al. (2018b) resulted to
be highly divergent while it correspond to the main haplotype
described in this study using only cox1.
All cases of camel CE were caused by E. granulosus s.l.
G6/G7. Even more importantly, a common haplotype exists
between camels and humans, which is notably the main
representative haplotype for both the species and is found in
the same geographic area. A maximum of two mutations was
identified between the haplotypes from human and animal
samples. The two haplotypes M2 and M3 identified in
human cases of E. granulosus s.l. G6/G7 using short cox1
sequences from Jabbar et al. (2011) correspond to haplotypes
1 and 2 and haplotypes 3 and 4, respectively, as both pairs are
identical for the 363 bp concerned. A higher genetic diversity
may be expected in this regard if camels comprised a larger
sample, including additional areas, possibly leading to the
identification of other shared haplotypes from previously
identified human cases, since camels appear to be the main
intermediate hosts for E. granulosus s.l. G6/G7 in Mongolia.
The molecular investigation conducted on human CE cases in
Mongolia found that most children cases were caused by the
E. granulosus s.l. G6/G7 species, while those of adults were
caused by both E. granulosus s.l. G6/G7 and E. granulosus
s.s. (Ito et al. 2014; Shirmen et al. 2018). Therefore, our results
indicate the importance of camel role in current burden of
echinococcosis in Mongolia. However, further research is re-
quired to assess the prevalence of CE in sheep and goats, in
order to confirm this observation.
Fig. 4 Geographical distribution of haplotypes of E. granulosus s.l. G6/
G7 in Mongolia. The average camel density between 2006 and 2016 is
plotted as a base-layer for each “soum” (gray choropleth). Distributions of
E. canadensisG6/G7 from human, camel, and goat cases are presented by
pie chart, bar graph (square), and triangle point, respectively. The genetic
differences in both human and animal samples are presented by number
of mutations (blue color scale) compared to haplotype EcMGL2 (Ito et al.
2014) (haplotype 1 in current study) as a reference. UB Ulaanbaatar, the
capital city of Mongolia
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This study provides the first report on E. granulosus s.l.
G6/G7 infection of goats in Mongolia (Deplazes et al. 2017).
Goats are the main animals that share pasture with camels in
Mongolia (Appendix 2). Our statistical analysis, however, did
not find an association between human CE cases and goat
population density. Although our results might be suggesting
that goats are more of a spillover host for E. granulosus s.l.
G6/G7, we cannot draw firm conclusions without additional
parasite data of CE-infected goats from other southern prov-
inces with a high prevalence of human CE. Further investiga-
tion is required to clarify the role of goats in the transmission
of CE and E. granulosus s.l.G6/G7, including comparisons of
the grazing and/or drinking behavior of and ecology among
these livestock (Lawson and Gemmell 1983).
Interestingly, in the liver cysts of two camels included in the
sample, two different cox1 haplotypes (1 and 2) were identified,
indicating mixed infections. This could be explained by succes-
sive infections, simultaneous infection with eggs from a defini-
tive host harboringwormswith both haplotypes, or possibly even
contamination of the same area by two definitive hosts harboring
worms with different haplotypes. Mixed infection was previous-
ly reported for E. granulosus s.s. in studies that tested multiple
cysts from the same intermediate host, but this occurs infrequent-
ly (Boufana et al. 2014; Casulli et al. 2012; Umhang et al. 2014;
Umhang et al. 2013). To the best of our knowledge, this is the
first time that the presence of mixed infections of E. granulosus
s.l. G6/G7 with different haplotypes has been confirmed in the
intermediate host. These mixed infections involve the two most
frequent haplotypes identified in the camels described here
(Appendix 1).
We identified the common haplotype in one of the twowolves
whichwere previously described (Ito et al. 2013). Theremight be
marked differences concerning the accessibility of intermediate
hosts’ offal, for definitive hosts to be infected. Camel offal is
more likely to be left in the field during the slaughtering process
owing to its large volume and can become accessible to wild
canids and stray dogs, whereas offal from small ruminants would
be collected by the herders to feed their own dogs. Another
consideration is that the previously reported human CE samples
were collected in 2009, while our field survey was conducted in
2016, which might also highlight consistency regarding the
source of infection in the same geographic region.
We were unable to consider infections in dogs due to the
absence of existing data. Every rural family has at least one to
twowatch-dogs. In particular, the children in these rural areas are
highly exposed to dogs, as discussed in the national stakeholder
meetings (Gurbadam et al. 2010). A nationwide surveying of
dogs and livestock remains an urgent task to gain an overview
of the current CE endemicity in Mongolia. While E. granulosus
s.s. is a still an important agent in Mongolia, in areas with high
camel density, the presence of E. granulosus s.l.G6/G7 needs to
be considered as an equally significant threat to public health,
especially for children. The insights provided by this paper
suggest that priority interventions should aim at affecting behav-
ioral change by improving hand hygiene, proper disposal of offal
at home, private slaughtering, and deworming of dogs.
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Appendix 1. List of samples according to animal species, organ and geographical origin. The 
complete cox1 haplotype of E. granulosus s.l. G6-7 is indicated with detail for each cyst sampled 
when two different haplotypes were identified. 
       
N 
Animal 
species 
geographical origin 
number of 
cysts 
sampled 
organ 
infected 
complete cox1 
haplotype 
Province Soum* 
   
1 Camel Khurmen 
Khuren 
zaw 1 liver 4 
2 Camel Khurmen 
Khuren 
zaw 1 liver 2 
3 Camel Khurmen 
Khuren 
zaw 2 liver 2 
4 Camel Khurmen Khadan us 1 liver 2 
5 Camel Khurmen Khadan us 3 liver 2 
6 Camel Khurmen Khadan us 4 liver 1 (n=1), 2 (n=3) 
7 Camel Khurmen Khadan us 2 liver 1 (n=1),2 (n=1) 
8 Camel Khurmen Khadan us 2 lungs 1 
9 Camel Khurmen Khadan us 1 liver 2 
10 Camel Khurmen Khadan us 1 lungs 2 
11 Camel Khurmen Khadan us 2 lungs 3 
12 Camel Khurmen 1r bag 1 liver 1 
13 Camel Khurmen 1r bag 1 liver 2 
14 Camel Khurmen 1r bag 2 liver 3 
15 Camel Khurmen 1r bag 1 liver 1 
16 Camel Khurmen 1r bag 1 liver 1 
17 Camel Khurmen 1r bag 2 lungs 1 
19 Camel Khurmen NA 1 liver 3 
20 Camel Khurmen NA 1 liver 1 
18 Goat Khankhongor Bumbat 2 liver 1 
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Appendix 2. Geographical distribution of cattle, sheep, camel, goat in Mongolia 
(average between 2006-2016) 
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Abstract
Background
Mongolia is one of the endemic countries for cystic echinococcosis (CE), a zoonotic disease
caused by the larval stage of Echinococcus granulosus. The goal of this study is to describe
the current clinical management of CE in Mongolia, to capture the distribution of cyst stages
of patients treated, and to contrast current practice with WHO-IWGE expert consensus.
Methods
Hospital records of CE patients treated between 2008 and 2015 at the three state hospitals
and fulfilling the inclusion criterion ‘discharge diagnosis CE’ (ICD 10 code B.67.0–67.9)
were reviewed. Demographical, geographical, clinical and ultrasonography (US) data were
extracted and analyzed. The annual surgical incidence was estimated. The digital copies of
US cyst images were independently staged by three international experts following the
WHO CE cyst classification to determine the proportions of patients which ideally would
have been assigned to the WHO recommended treatment modalities surgery, percutane-
ous, medical (benzimidazole) treatment and watch & wait.
Results
A total of 290 patient records fulfilled the inclusion criteria of the study. 45.7% of patients
were below 15 years of age. 73.7% of CE cysts were located in abdominal organs, predomi-
nantly liver. US images of 84 patients were staged and assessed for interrater-agreement.
The average raw agreement was 77.2%. Unweighted Kappa coefficient and weighted
Kappa was 0.57 and 0.59, respectively. Mean proportions of images judged as stages CE1,
CE2, CE3a, CE3b, CE4 and CL were 0.59, 0.01, 0.19, 0.08, 0.03 and 0.11, respectively. 40
cysts met the inclusion criteria of treatment modality analysis. The mean proportions of
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cases with a single cyst assigned to medical, percutaneous treatment, surgery and watch &
wait were 52.5% (95% CI 42–65), 25.8% (95% CI 15–30), 5.1% (95% CI 0–10) and 3.3%
(95% CI 0–10), respectively. 13.3% (95% CI 5–25) of cysts were staged as CL and therefore
assigned to further diagnostic requirement.
Conclusion
WHO CE cyst classification and WHO-IWGE expert consensus on clinical CE management
is not implemented in Mongolia. This results in exclusively surgical treatment, an unneces-
sary high risk approach for the majority of patients who could receive medical, percutaneous
treatment or observation (watch & wait). Introduction of WHO-IWGE expert consensus and
training in ultrasound CE cyst staging would be highly beneficial for patients and the health
care services.
Author summary
Cystic Echinococcosis (CE) is a zoonotic disease, commonly known as dog tapeworm.
The disease is distributed globally and predominantly affects rural populations with lim-
ited access to health care. Following the expert consensus of the WHO-Informal Working
Group on Echinococcosis (WHO—IWGE) patients with uncomplicated cysts are assigned
on the basis of WHO cyst classification to four treatment modalities: medical (benzimid-
azoles), percutaneous, surgical treatment, and ‘watch & wait’. In Mongolia, one third of
the population practices nomadic farming. These populations are heavily affected by CE.
However, cyst staging and WHO-IWGE recommendations are not implemented and
patients referred to the three national treatment centres receive surgical treatment. This
exposes a large proportion of patients to an unnecessary high risk approach who could be
treated–depending on cyst stage—with benzimidazoles, percutaneously or observed
(watch & wait). We reviewed the hospital records of patients with CE and admitted
between 2008 and 2015 to the three national CE treatment centres, retrospectively staged
the cysts and assigned the patients to the four WHO-IWGE recommended treatment
modalities. We found a high proportion of patients in the study population who would
have most likely benefitted from non-surgical treatment options.
Introduction
Cystic echinococcosis (CE) is a zoonotic disease caused by the larval stage of Echinococcus
granulosus. The life cycle of E. granulosus is maintained between the dog as the definitive host
and various livestock as the intermediate host. Humans are considered as an aberrant interme-
diate host. Ingested larvae develop into cystic lesions, mostly in the liver and lung [1]. The dis-
ease is globally distributed including Central Asian countries and China [2–4]. The annual
global burden of disease is estimated at 184,000 Disability Adjusted Life Years (DALYs) [5, 6].
Due to a large proportion of asymptomatic cases and underreporting the disease burden is
widely underestimated. Pastoral communities in countries with limited resources bear the
greatest burden [3, 5, 7].
In Mongolia, one-third of the population is engaged in extensive pastoral farming. The
presence of a large livestock population accompanied by watchdogs, a big number of stray
Clinical management of cystic echinococcosis in Mongolia
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dogs, unregulated private slaughtering, and lack of health education are the main reasons for
the heavy human CE exposure [8, 9]. Historically, due to strong public and veterinary action,
the surgical cases decreased from 13% in 1946 to 2% in 1988 in the state hospital [10, 11]. After
the Soviet Union collapsed in 1990, the veterinary and public health sectors weakened and
many control programs for zoonotic disease, including CE, collapsed [12]. Currently, CE is
not included in the national surveillance system, and official statistics are, therefore, unavail-
able [8, 9, 13]. There are few reports on the current transmission of CE in Mongolia including
small scale serological surveys, hampered, however, by the sensitivity and specificity problems
of serological CE testing [11, 14–18].
CE predominantly affects rural populations with very limited access to health care [19].
Diagnosis, cyst staging, treatment and follow-up depend on imaging [20, 21]. Ultrasonogra-
phy, however, is only recently introduced in low and lower middle income countries (LICs
and LMICs)[22–24]. Thus most endemic countries, including Mongolia, have not yet imple-
mented the WHO Informal Working Group on Echinococcosis (WHO-IWGE) expert con-
sensus [25, 26]. The core piece of the WHO-IWGE expert consensus is to triage on the basis of
ultrasound-defined cyst stages into four groups: medical, percutaneous, surgical treatment
(active cyst stage CE1 to CE3b) and ‘watch & wait’ (inactive cyst stages CE4 and CE5) [20, 27–
30].
The goal of this study is to describe the current clinical management of CE in Mongolia, to
capture the distribution of cyst stages retrospectively from stored ultrasound images, to criti-
cally contrast current practice in Mongolia with WHO-IWGE expert consensus and to suggest
a LIC / LMICs-adapted implementation strategy for WHO-IWGE expert consensus.
Materials and method
Ethics statement
This work presented here was approved by the Medical Ethics committee of Mongolia (July
2014) and WHO ERC (27 Nov 2015).
Study area and data collection
We reviewed the hospital records of patients diagnosed with CE and admitted between 2008
and 2015 to the three state hospitals conducting CE surgery in Mongolia: First Central Hospi-
tal (FCH), Third Central Hospital (TCH), National Center for Maternal and Child Health
(NCMCH). Patients identified as probable CE cases in the peripheral or secondary hospitals
are, as a rule, referred to the three state hospitals for confirmation and surgery. In the archives
of the state hospitals, the medical records are chronologically stored in bundles of 150–200
reports. On the front page of each record the discharge diagnosis is recorded by the surgeon,
based on histopathology which is done as a routine in the national hospitals. The ‘discharge
diagnosis CE’ (ICD 10 code B.67.0–67.9) was the inclusion criteria for our study.
The following data were extracted from the patient records on data extraction sheets: demo-
graphic and geographic data (specified in Table 1), clinical symptoms and signs, ultrasonogra-
phy (US) reports including number and size of cysts, US images, surgical reports and final
diagnosis. US images (photos) were digitalized and stored. The data collected on data extrac-
tion sheets were double entered into a data base.
Data analysis
The demographic information including age, sex, occupation, type of home, and distance
from health care was presented with the relevant percentage. The distance between secondary
Clinical management of cystic echinococcosis in Mongolia
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hospital (provincial general hospital) and current address of the patient was calculated. The
levels of the clinical care in Mongolia are provided in Fig A in S1 Appendix.
The socio-economic status (SES) in the adult patients was stratified according to the labour
force category of the National Statistical Office [31]. The current address of the patient was
used to plot the geographical distribution by employing the ArcGIS 10.0 (ESRI 2011. ArcGIS
Desktop: Release 10. Redlands, CA: Environmental Systems Research Institute). The annual
surgical incidence was estimated based on the hospital records. The frequency of the clinical
signs & symptoms was calculated. The size and number of CE cysts were presented in three
different categories, <5 cm, 5–10 cm, and >10 cm and single cyst, 1–3 cysts, and multiple
cysts, respectively.
The digital copies of US cyst images were independently reviewed by three international
experts (reviewers) to estimate the frequency distribution of cyst stages according to WHO
cyst classification (CL, CE1, CE2, CE3a, CE3b, CE4, CE5) in the patient population referred to
the state hospitals for confirmatory assessment and treatment. The exercise was performed on
the US images of abdominal lesions. The experts received no further information about the
patients. Duplicate images of cysts were provided when available. If the reviewer felt unable to
Table 1. Demography, socio-economic status (SES) and geographical data of the patients.
Patient characteristics Frequency
n %
Age
<14 113 45.7
15–59 116 47.0
>60 18 7.3
Total 247 100
Sex
Male 116 47.0
Female 131 53.0
Total 247 100
Occupation
Paid employee 42 34.4
Self-employed 16 13.1
Employed in animal husbandry 12 9.8
Unemployed/retired/disabled 52 42.6
Total 122 100
Distance from secondary level hospital
<100 km 107 62.2
100 km-200 km 53 30.8
>200 km 12 6.9
Total 172 100
Type of home
Apartment 47 19.0
Yurt 200 81.0
Total 247 100
- 60 pediatric cases and 65 cases without information on employment were excluded from calculating the
percentage of occupation.
- 60 cases from Ulaanbaatar city and 15 cases without an exact address were excluded from calculating the
percentage of distance
https://doi.org/10.1371/journal.pntd.0006686.t001
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stage a cyst, e.g. because of poor quality of an image, the cyst was classified ‘not identifiable’
(NI). After the assessment, exclusions were made on the double images. If a double image of a
cyst was assessed identical by the reviewers, we selected randomly one of the images. If a dou-
ble image was assessed not identical by the reviewers, the one with fewer “NI” votes was
selected to represent the cyst. Interrater-agreement was calculated using the Kappa statistic.
Raw agreement was calculated as the proportion of cysts where the raters noted the same stage
and kappa statistics for ordered categories (CL, CE1, CE2, CE3a, CE3b, CE4, CE5). We report
both, unweighted and weighted kappa statistics with weights calculated as the square of the
distance between the two ordinal groups. We judged agreement as poor if κ< 0.2; fair if 0.2
κ< 0.4; moderate if 0.4 κ< 0.6; substantial if 0.6 κ< 0.8; and good if κ 0.8. The esti-
mates represent the arithmetic mean of the 3 pair-wise comparisons. “NI” judgements were
considered as missing values which have been excluded pair-wise for raw agreement and
kappa estimation.
Allocation of the cysts to WHO recommended treatment modalities was performed on the
basis of cyst staging by the 3 reviewers and cyst size. Cases with images assessed as “NI” by all
three reviewers were excluded; equally, cases with more than one cyst since completeness and
ascertainment of US images was difficult retrospectively. The double images were excluded
using the same algorithm as in the analysis of interrater-agreement. We calculated combina-
tions of CE stage and cyst size for all three reviewer assessments separately and calculated the
mean percentage. Based on this combination, the probability of assignment of cases to the
treatment modalities as defined by the WHO-IWGE expert consensus were estimated for each
case. Assignment of cysts to WHO recommended treatment modalities was performed as if all
cysts were uncomplicated since the retrospective data did not allow to reliably differentiate
complicated from uncomplicated cysts. Bootstrap resampling with 10,000 replicates was used
for estimating the 95% confidence intervals for the treatment options. The analysis was con-
ducted using the statistical package R v 3.4.0.
Results
A total of 290 medical records fulfilled the inclusion criterion ‘discharge diagnosis CE’ (ICD
10 code B.67.0–67.9) of the patients admitted to the three state hospitals between 2008 and
2015, 43 records were excluded. For details see Fig 1.
The demographic data are presented in Table 1.
During the period 2008–2015, the average annual CE surgical incidence per 100 000 was
1.06 (95% CI 0.7–1.4) based on the current data collection. On average 30.8 (95% CI 20.4–
41.3) cases per annum underwent CE surgery in the central hospitals between 2008 and 2015
(Fig B in S1 Appendix).
The patients originated from 20 provinces corresponding to 95% (20/21) of all provinces
(Fig 2). The southern provinces Omnogobi (OG), Dundgobi (DU), and Bayankhongor (BH)
have the highest number of cases. Average CE surgical incidence for the survey period in these
provinces was 2.7–6.1 per 100 000 inhabitants based on the medical records in the three state
hospitals.
The frequency of symptoms & signs in CE patients at admission to the three state hospitals
are provided in Fig C in S1 Appendix. The location of CE cysts of the surgically treated patients
at the three state hospitals between 2008 and 2015 are provided in Fig D in S1 Appendix.
Preoperative ultrasound reports were available in 83.5% (152/182) of patients who had
undergone abdominal surgery for CE. 26.3% (40/152) were explicitly recorded as hydatid
cysts, 54.6% (83/152) as cystic lesions, and 19% (29/152) as other space occupying lesions.
99.3% (151/152) of the abdominal cases had the information on the cyst number in the US
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record. Among them, 78.1% (118/151) had single cysts, 20% (31/151) had 1–3 cysts and 1.3%
(2/151) had more than 3 cysts. The information on size was available for 90.1% (137/152) of
the abdominal cases. Among them, 48.9% (67/137) had cysts smaller than 5 cm, 35.0% (48/
137) of 5–10 cm and 16.1% (22/137) were bigger than 10 cm.
138 US imaging photos of 84 cases with liver and abdominal cysts were available for review
and CE cyst staging based on the WHO CE cyst classification by three international reviewers.
Following the inclusion / exclusion procedures described in the method section images of 84
unique cysts were assessed for interrater-agreement analysis. The raw agreement was 77.2%.
We observed substantial agreement with an average unweighted Kappa coefficient of 0.57 and
an average weighted Kappa coefficient of 0.59 (squared weights). The proportions of CE cyst
stages are shown in Fig 3. Mean proportion for CE stages including CE1, CE2, CE3a, CE3b,
CE4, and CL were 0.59, 0.01, 0.19, 0.08, 0.03 and 0.11, respectively. No CE5 cysts were
identified.
Of the cysts staged by the three reviewers, 40 met the inclusion criteria for the treatment
modality analysis (selection process see methodology section). The mean proportion of cases
assigned to medical treatment, percutaneous treatment, surgery and watch & wait was
Fig 1. Selection of CE surgical case records. (a) 290 records (patients) in the 3 state hospitals in Mongolia fulfilled the
inclusion criterion ‘discharge diagnosis CE’ (ICD 10 code B.67.0–67.9); (b) 12 records (patients) were excluded
because the patients have not been operated on (4 surgeries postponed, 3 post-surgical conditions, 4 calcified cysts not
needing surgery, 1 no information), 11 because of missing surgical information, 20 records belonged to 15 patients
who were re-admitted once or twice; (c) 247 cases were analyzed.
https://doi.org/10.1371/journal.pntd.0006686.g001
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calculated as 52.5% (95% CI 42–65), 25.8% (95% CI 15–30), 5.1% (95% CI 0–10) and 3.3%
(95% CI 0–10), respectively. 13.3% (95% CI 5–25) of the cysts were staged as CL in need for
further diagnostic work up (Fig 4).
Fig 2. Average CE surgical incidence in each province for the period 2008–2015. Abbreviations: BO-Bayan-Olgii,
UV-Uvs, HD-Khovd, ZA-Zavkhan, GA-Gobi-Altai, BH-Bayankhongor, OH-Ovorkhangai, AH- Arkhangai,
HG-Khubsgul, BU-Bulgan, DA-Darkhan, SE-Selenge, ER- Orkhon, UB-Ulaanbaatar, DU-Dundgobi, OG-Omnogobi,
TO- Tov, DG-Dornogobi, HN-Khentii, DD-Dornod, GS-Gobisumber., SB-Sukhbaatar.
https://doi.org/10.1371/journal.pntd.0006686.g002
Fig 3. Distribution of CE cyst stages on the basis of the WHO CE cyst classification. The average proportions (big
diamond) of CE cyst stages staged on the basis of the WHO CE cyst classification by the three experts. r1, r2, r3 are the
proportions (small diamonds) of CE cyst stages classified by the expert 1, 2, and 3, respectively.
https://doi.org/10.1371/journal.pntd.0006686.g003
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Discussion
To the best of our knowledge this is the first description of the clinical management of CE
patients in LICs / LMICs with an attempt to critically contrast current national practice with
the WHO-IWGE expert consensus [20] on the basis of interrater-agreement calculated from
the retrospective cyst staging by three independent experts. Mongolia offers the unique oppor-
tunity for this exercise for two reasons. CE patients identified on the peripheral level of the
health care services are exclusively referred for confirmation and treatment to the three state
hospitals where patient records are carefully stored in archives with a discharge diagnosis on
the front page of each patient file. The data of 290 patients with the ‘discharge diagnosis CE’
(ICD 10 code B.67.0–67.9) admitted between 2008 and 2015 were available to characterize the
CE patients who currently receive treatment in Mongolia. Ultrasound photos of 46% (84/182)
of patients with abdominal cysts were available for retrospective cyst staging on the basis of
WHO CE cyst classification by three international experts. Based on the retrospective staging
result and size, proportions of assignment to WHO-IWGE recommended treatment modali-
ties were estimated.
The socio-demographic characteristics of the study population receiving treatment at the
three state hospitals show some interesting features. Around 50% of the patients are below 15
years of age. In Kazakhstan and Kyrgyzstan, countries in the same region as Mongolia and
with a similar pastoral lifestyle, also reported high proportion of children among the surgical
cases [3]. Equal proportions of male and female patients suggest that, understandably, the
infection risk is equal with CE transmitted in a food borne dog faecal-human oral cycle. Dis-
tance to the secondary hospital is a relevant factor for access to specialized health care in all
LICs and most MICs [32, 33]. About 40% of the surgical patients had to travel at least 100 km
to reach the secondary hospitals. Besides the geographic barrier other factors might contribute
to underreporting but currently no data are available. 80% of the patients are living in a “yurt”
Fig 4. Assignment of CE cysts of the study population to WHO-IWGE recommended treatment modalities on the
basis of retrospective cyst staging by three international experts. In uncomplicated CE cysts WHO-IWGE
recommended assignment of patients to the four treatment modalities surgery, percutaneous methods, drug treatment
(albendazole, mebendazole) and watch & wait is based on cysts stage and size (three groups). A Three size groups and
the average percentages of WHO cysts stages in the study population as retrospectively staged by three international
reviewers. Although there was a small percentage (1%) of CE2 identified by the three reviewers (Fig 3) this stage could
not be included into the analysis because the information on cyst size was lacking. CE5 was excluded since none of the
reviewers attributed one of the cysts presented for retrospective staging to CE5. B Based on the matrix in A, the
probability of assignment of patients to the WHO-IWGE recommended treatment modalities is presented. The grey
shading of the cells in A and B matrices correspond to each other. Cysts staged as CL would have needed further
diagnostic work up.
https://doi.org/10.1371/journal.pntd.0006686.g004
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which suggest that these patients are exposed to the combination of poor infrastructure, poor
water and sanitation and frequent contact with watch-dogs and their faeces [34, 35].
A significant proportion of patients presented with non-specific symptoms, around 20%
with abdominal pain corresponding to 29% of the patients with abdominal cysts. Around
16.6%, 8.5% and 6.9% of all patients had cough, chest pain and dyspnoea, respectively. This
amounts to 50%, 32%, and 14%, respectively, of patients with lung cyst. These results are in
line with the clinical experience that most patients present with non-specific symptoms and
signs [36]. Fever, observed in 22.3% of all admissions, may, however, indicate that some
patients had complication such as a cysto-biliary fistula with secondary bacterial infection of
the cyst or cholangitis associated with biliary obstruction due to spillage of cyst content into
the biliary tree; the latter also causes abdominal pain [37]. Similarly, patients with lung cysts
may have had fever due to pneumonia following bronchial compression caused by expanding
cysts or secondary bacterial infection of the residual cavity after the cyst content has been
expectorated via a cysto-bronchial fistula. Both complications are associated with cough and
dyspnoea [38]. Care should be exercised, however, to not over interpret retrospectively non-
specific signs and symptoms such as fever, documented in medical records.
Most patients had only a single cyst in abdominal organs of which almost 50% had a diame-
ter equal or smaller than 5 cm. This alone casts doubts on the indication for major surgery. If
uncomplicated, these cysts would—following the WHO-IWGE expert consensus—either fall
in the medical treatment group, if active (CE1 to CE3), or the watch & wait group, if inactive
(CE4 and 5).
Only 40 reports of the 182 abdominal cysts examined by ultrasound spelled out “hydatid
cyst” as the US diagnosis, without, however, mentioning accepted US criteria and without an
attempt to stage with the WHO-IWGE or Gharbi classification.
The most exciting part of this data set was the unique opportunity to review and retrospec-
tively stage 138 US imaging photos of 84 patients by three international experts to compare
current practice in Mongolia with WHO recommended treatment modalities [20]. The distri-
bution of WHO cyst stages retrospectively analysed from a subset of patients treated between
2008 and 2015 at the three state hospitals in Mongolia showed proportions of 0.59, 0.01, 0.19,
0.08, 0.03 and 0.11 for CE1, CE2, CE3a, CE3b, CE4, and CL, respectively (see Fig 3). Given the
relatively high number of categories, the observed raw agreement of about 80% and Kappa
coefficients of close to 0.6 indicate that the method appears to be generally valid but with room
for improvement. A similar result was found in a recent study assessing interrater-agreement
of the WHO cyst classification based on 2-D US images. The authors emphasized that an
improvement can be achieved when non-static imaging (video recording etc.) is incorporated
in future studies [39].
Assignment of patients to the WHO-IWGE recommended treatment modalities takes into
account cyst size in addition to cyst stage. Merging the cyst sizes with the retrospective WHO
cyst staging of the study population provides an insight into deviations of current practice in
Mongolia from the WHO-IWGE expert consensus. Of particular significance for patients
regarding unnecessary treatment risks and for the health care services with respect to avoidable
treatment costs is the fact that 3.3% of abdominal cysts would have not warranted any treat-
ment at all since they were already in an inactive stage (CE 4). Following the WHO-IWGE
expert consensus they would have been submitted to the watch & wait approach with a very
high probability of no need for further treatment [28, 29]. 52.5% of active abdominal cysts
(CE1 to CE3) with a diameter of 5 cm or smaller would have been submitted to medical treat-
ment following the WHO-IWGE expert consensus [20, 40]. This draws attention to the fact
that availability of albendzole, the preferred benzimidazole for CE therapy, is hugely lacking in
Mongolia. Currently, the price of albendazole is very high with approximately USD 2 per
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400mg tablet. Albendazole is mostly sold in pharmacies in cities, which also limits access.
Access to albendazole is a very much debated issue in the care for the neglected tropical disease
echinococcosis in neglected populations [41]. In addition to albendazole cost, 10–15% of the
hospital admission fee of public hospital is paid by the patients and the remaining cost is cov-
ered by the national health system in Mongolia [42]. However, there are many other costs
including informal fees to clinicians and advanced diagnostics increasing the economic bur-
den CE patients have to carry. Almost 26% of the patients assessed would have been allocated
to percutaneous treatment (PT). PT options are generally underused and are not carried out in
Mongolia for CE management due to a lack of trained personnel. Introducing PT into Mongo-
lia should be considered because it carries less risks for the patients, reduces treatment cost
and length of hospital stay. A study in Bulgaria showed similar deviations from best practices
as recommended by WHO-IWGE expert consensus[43].
There are several limitations of the study. The data were extracted retrospectively from
patient files. The fact that in Mongolia CE patients are being treated exclusively at the three
state hospitals with high standards of documentation and archiving compensated partly for
this shortcoming. Also, cyst staging was retrospectively performed on the basis of 2-D ultra-
sound photos. Our interrater-agreement of retrospective cyst staging, however, gives confi-
dence that the staging result provides an acceptable estimate of the distribution of cyst stages
seen at the three national hospitals. Identifying complicated cysts is difficult in retrospective
studies. In some instances we could suspect that a cyst was complicated by combining various
pieces of available retrospective information (e.g. fever, abdominal pain plus US cyst features
suspicious of secondary bacterial infection of a cyst). This, however, is all too vague and would
be an over interpretation of retrospective data. We thus did the analysis “as if” the cysts of the
US images classified were uncomplicated. This may have resulted in an overestimate of the
non-surgical treatment modalities.
In conclusion, our study demonstrates
1. Mongolia has a significant section of the population suffering from cystic echinococcosis
and is in need of implementing a LMIC-adapted version of the WHO-IWGE expert
consensus
2. Access to the privileged treatment centres, the three state hospitals, may be limited by geo-
graphic distance and economic resources
3. Ultrasonography is available, but diagnostic CE criteria seem not to be sufficiently well
known and cyst staging is not performed
4. WHO-IWGE expert consensus for assigning patients to the four treatment options based
on CE cyst staging and cyst size are not implemented resulting in surgical treatment of all
CE patients and in an unnecessary high risk approach in patients who could be treated with
albendazole or percutaneously or observed (watch & wait).
It is recommended
1. To systematically include CE into the disease surveillance system of Mongolia
2. To make ultrasonography available to the primary / secondary health care level and to
train local, physicians in the WHO CE cyst staging. The Focused Assessment with
Sonography for Echinococcosis (FASE), a short course for general practitioners, could
be a model [26]. In 2016, a pilot training was conducted on WHO-CE cyst classification
and staging for primary/secondary ultrasonography doctors by leading experts in the
field.
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3. To introduce and implement the WHO-IWGE expert consensus at all levels of the health
care system to triage patients into the four WHO treatment modalities (a) medical treat-
ment of small active cysts, (b) percutaneous treatment of larger active cysts (CE 1 and CE
3a), (c) surgery for complicated, very large cysts and cysts unresponsive to medical therapy,
and (d) watch & wait for inactive cysts (CE4 and 5). Implementation at the primary and sec-
ondary health care levels saves transport cost, travel time for patients and allows a substan-
tial proportion of patients to stay near or in their homes during treatment.
4. To apply our strategy of assessing CE clinical epidemiology and management in other CE
endemic LICs / LMICs as a basis for planning.
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S1 Appendix 
 
Fig A.  CE management provided at the three levels of health care in Mongolia 
 
*- smaller administrative unit of province 
**- smaller administrative unit of district 
 
 
 
Fig B. CE surgical cases per year, 2008-2015 
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 Fig C. Clinical symptoms and signs at admission to the three state hospitals 
 
Numbers in bars represent Nreported/Ntotal. 
 
Fig D. Locations of CE cysts of the surgically treated patients at the three state 
hospitals between 2008 and 2015 
 
*Not analyzed for CE cyst stages (WHO CE cyst classification) due to unavailability of the X-ray films or other appropriate imaging
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6.1 Abstract 
 
Background: Ultrasonography has developed into a powerful tool for diagnosing and 
staging CE. WHO-CE cyst classification dividing cysts into active (CE1, 2, 3a, 3b) and 
inactive (CE4,5) is the basis for tailoring the four treatment options albendazole, 
surgery, percutaneous methods and watch & wait to patients. The classification is still 
grossly underused in most epidemic countries including Mongolia. Our objective was 
to explore the knowledge and use of  WHO-CE cyst classification and current clinical 
management in Mongolia. 
 
Method: A questionnaire on the WHO-CE cyst classification and CE patient 
management was issued to clinicians of rural health care centres in charge of 
ultrasound services and a Focus Group Discussion on clinical management of CE 
conducted with health professionals. 
 
Results: The ultrasonography doctors in rural health centers have a pivotal role in 
clinical decision making. However, an unstandardized diagnostic approach and an 
uncertainty of available treatment in local hospitals are the main challenges, leading 
to a lack of diagnostic confidence. The majority (90%) of the clinicians did not know 
about the WHO-IWGE algorithm and all willing to participate in the training 
program.  
 
Conclusion: The majority of the CE patients are from remote, rural areas and have 
great difficulty in accessing health services. An optimization or standardization of the 
current CE clinical management in rural hospitals can largely prevent the clinical and 
financial burden of patients. The training of ultrasonography doctors with WHO-
IWGE expert consensus is the key step for standardization of the clinical management.  
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6.2 Introduction 
        
     
      
       
    
       
  
        
   
        
      
        
 
Ultrasonography, however, is only recently introduced in low and lower middle 
income countries (LMICs)(Groen et al., 2011; Becker et al., 2016; Belard et al., 2016). 
Thus most endemic countries, including Mongolia, have not yet implemented the 
WHO Informal Working Group (WHO-IWGE) expert consensus.  
 
 
Our main objective was to identify the key challenges for optimization of clinical 
algorithm for CE in Mongolia and propose the optimized algorithm. We conducted 
following activities: 
  
2. Questionnaire on WHO-IWGE and stage specific treatment: 
3. One round Delphi survey on clinical management of CE 
 
6.3.1 Focus Group Discussion  
 
 
Study area: General Hospital (GH), of Dalanzadgad city (provincial center) in 
Omnogobi province. 
Participants: Director of the clinical service of GH; Epidemiologist of GH; Senior 
imaging  doctor of  GH; Senior  doctor for  internal  medicine of GH;  Surgeon at GH; 
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6.3 Materials and methods
Ultrasonography has developed into a powerful tool for diagnosing and staging cystic
echinococcosis (CE) (Brunetti et al., 2010; Stojkovic et al., 2012). There two main 
staging algorithm used in the world: Gharbi et al., (1981) and WHO-CE classification 
recommended by the WHO – Informal Working Group on Echinococosis (WHO- 
IWGE) (Gharbi et al., 1981; Brunetti et al., 2010). The updated version from WHO- 
IWGE has an advantage of using stage specific treatment option and accounts the re- 
activation of the cyst which can change the whole prognosis of the patient. The core 
piece of the guidelines is to triage on the basis of ultrasound-defined cyst stages into
four groups: medical, percutaneous, surgical treatment (active cyst stage CE1 to CE3b) 
and ‘watch &wait’ (inactive cyst stages CE4 and CE5) (Junghanss et al., 2008; Brunetti 
et al., 2010; Piccoli et al., 2014; Stojković et al., 2014; Stojkovic et al., 2016). The 
classification is still grossly underused in most epidemic countries (Del Carpio et al., 
2012; Tamarozzi et al., 2014; Nabarro et al., 2015).
1. Focus Group Discussion (FGD)
The main  goal  of  the FGD  was to  get  first  insight  in to  a perspective of  rural 
health professionals in CE management.
 	   
Chief of statistician at of Provincial Health Department (PHD); Director of Zoonotic 
Center in Omnogobi; Epidemiologist of Zoonotic Center of Omnogobi; General 
practitioner in Dalanzadgad city 
 
        
     
 
 
1. Although CE patients are rare, it is increasing 
2. Most CE suspected patients referred to surgery  
3. There are no standard approach for diagnosing CE. 
4. Staging does not practiced. 
5. The pathognominic signs: “water-lily” shape, “honeycomb like” shape, or 
“umbrella” are listed in the clinical guideline of chronic diseases.  
6. CE does not get listed in the Notifiable disease list 
 
6.3.2 Questionnaire on WHO-IWGE and stage specific treatment 
 
The main objective was to identify applicability of WHO-IWGE cyst classification in 
General Hospital in provinces (secondary level hospital). 
Study area: 12 provinces  
Participants: A total of 31 clinicians from general hospitals in 12 provinces 
participated for the questionnaire 
Questionnaire (supplementary material) 
 
Preliminary result: 
90% have not heard of the WHO-IWGE consensus during their training or in 
professional experience. 60% answered that they do not follow any ultrasound 
diagnostic classification algorithm.  The main clinical managements are surgery  (37%) 
and monitoring (50%), while only 8% considered of using benzimidazole.  Almost all 
of the US doctors 94% (17/18) responded that they need additional training to staging 
the CE. 40 percent answered that patients are followed more than one year and others 
answered below one year. 
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FGD topic: frequency of CE suspected patients; management provided to CE 
suspected patients; what algorithm or guideline used for managing  CE patients;
usage of CE staging; how  do you register cases; how  to improve reporting; 
chal lenges
D iscussion outpu t:
 	  
 
6.3.3 One round Delphi survey on clinical management of CE 
 
The main goal was to identify the priority challenges for optimization of CE clinical 
management by asking from the health professionals who are most familiar with the 
situation. 
 
Study area: representatives from all 21 provinces 
 
Participants: The Delphi survey took during the Stakeholder meeting in 2016 
(Appendix 1). 44 health professionals from 21 provinces and the city.  A total of 17 
imaging doctors 17 provinces, 21 epidemiologists from 21 provinces and 2 
epidemiologists from the city participated in the exercise. 
 
Preliminary result 
 
Figure 1. Mean scores of each item in clinical management of CE in secondary level 
 
 
 
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
20.	Report	to	notifiable	disease	registration	II
19.	Parasitology	laboratory	II
18.	Albendazol	abundance	II
17.	Knowledge	of	albendazole	use	II
15.	Registration	of	CE	treated	patients	II
14.	Serology	tool	supply	II
12.	Histology	laboratory	II
13.	CE	staging	manuel	II
10.	Monitoring	frequency	(watch&wait)	II
9.	Registration	of	referral	 II
8.	Usage	of	diagnostic	manuel	for	CE	II
7.	Monitoring	frequency	(post-surgery)	II
6.	Usage	of	e-registration	II
5.	Trainee	of	3	months	US	course	II
4.	Knowledge	about	CE	II
3.	No.	of	imaging	doctors	II
1.	Supply	of	US	machine	II
Mean	score
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6.4 Discussion 
 
The inclusion of CE within the notifiable disease registry would not be successful, 
without clear case definition guided by the standard clinical guideline. All diagnostics 
of abdominal lesions heavily relied on the radiologists, but not all CE cases are 
reported in the digital system due to the uncertainty of the case definition. Moreover, 
all treatment options recommended by WHO-IWGE group except “watch & wait” is 
not available at the secondary level. There is no albendazole supply in the rural 
provinces, and its price is high. The surgery of CE does not conduct at the local level 
and only provided by the few surgeons in tertiary hospitals. Therefore, if the patients 
diagnosed with CE, they have to go to tertiary center at the city to get the required 
treatments, and they would not be hospitalized at the secondary level unless they 
reported with another disease that secondary level could provide service. Such 
situation puts the radiologists, internal doctors in a difficult situation to report CE, 
which causes so seldom report of CE in the statistical system of secondary level 
hospitals.   
 
The CE is highly local disease in Mongolia. Radiological, surgical doctors, have been 
studied extensively during 1950-1980 to improve the clinical management. We found 
at least two local proposals for classification of echinococcosis in 1990 (Sodov, 1990; 
Munkhtogoo, 1991). The pathognomonic features in ultrasound including “water-
lily” shape, “honeycomb like” shape, or “umbrella” signs, were familiar, which was 
also listed in the Clinical Guideline for Diagnostics of Common Disease (MoH, 2008). 
However, it is still a grey area, especially for young radiologists. Current radiologists 
graduates from two training system: 1)Medical school for specialized training and 2) 
Training from Mongolian Society of Diagnostic Ultrasound (MSDU) for primary and 
secondary health care specialists. 
 
6.4.1 Proposed algorithm flowchart 
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Based on the information, we developed a proposed diagnostic algorithm which is to
be discussed with  the national experts (Figure 2, 3).
 	  
 
 
Figure 2. Current clinical algorithm in Mongolia for CE in the abdominal organ  
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Figure 3. Proposed diagnostic algorithm for CE in abdominal organ (draft). The draft 
algorithm will be circulated to the national experts before finalization. 
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6.5 Supplementary material 
	
Questionnaire from health personnel about the 
current practice of cystic echinococcosis: 
General information on interview 
o Initials interviewer  ___________________________ 
o Date of interview   Day____ Month____ Year______ 
o Location of interview ___________________________ 
Ø Choose your profession:  
o Surgeon (local/national hospital) 
o Ultrasound imaging doctor ( local/ national hospital) 
o General practitioner (local/national hospital) 
o Other _____________________ 
Ø The years that your worked in your hospital? 
o 1-3 years 
o 4-7 years 
o 7 years< 
Ø Is cystic echinococcosis endemic in your area? 
o Yes 
o No 
Ø [if YES to question 3] What risk factors of cystic echinococcosis do you think exist in 
your province? 
o Most of the people have a 1 or more guard dogs 
o People often feed their dog with sheep or other livestock offal 
o Private slaughter slabs are abundant 
o Water and sanitation situation is poor in some area 
o Other, specify_______________________________________________ 
Ø How many patients with cystic echinococcosis come to seek your help last year? 
o Never 
o 1 or more times daily  
o 1 or more times weekly 
o 1 or more times monthly 
o 1 or more times yearly 
Ø What are the challenges in diagnosing cystic echinococcosis? [multiple choice] 
o Most of the ultrasonographic specialists in our hospital have no training 
for identifying CE 
!"
 	 o We do not organize telemedicine in our hospital to confirm the diagnose 
of cystic echinococcosis 
o Others____________________________________________________ 
 
Ø How many ultrasound machines run in your hospital 
o 0 
o 1 
o 2-4 
o More_________________ 
Ø [For ultrasound imaging doctors] Specify the time period of your US training? 
o 1 week-1 month 
o 1 -3 month 
o 4-6 month 
o 6 month – 2 years 
o Other [ specify the time period]__________________ 
Ø [For ultrasound imaging doctors] How long ago you had your last US training ( 
which included training on cystic echinococcosis)? 
o <1 year ago 
o 1-5 year ago 
o 5-10 year ago 
o 10 year ago< 
Ø Which cystic echinococcosis classification do you use? 
o The Gharbi classification 
o The WHO classification 
o None 
o Other_________________________________________ 
Ø Do you need more training to be confident with recognizing cystic echinococcosis 
cyst on US? 
o Yes 
o No 
o Don't know 
Ø How many patients do you see in a day? 
o 1-9 
o 10-19 
o 20-29 
o 30-39 
o 40< 
Ø How do you register cystic echinococcosis patients? [multiple choice] 
!"
 	 o Registration journal of ultrasound unit  
o Registration journal of X-ray unit 
o Registration journal of referral 
o Hospital statistical department  
o Other _________________________________________ 
Ø Are therapeutic choices for cystic echinococcosis available in your hospital? [multiple 
choice] 
o Albendazole  
o Surgery  
o PAIR  
o Watch and wait method  
Ø For how long do you follow-up the patients? 
o <1 year 
o 1-5 years 
o 5 years< 
Ø How do you follow up your patient? [multiple choice] 
o Phone (specify the frequency in a year _________________) 
o Home visits (specify the frequency in a year _________________) 
o Patients visits to hospital (specify the frequency in a year _________________) 
o Other__________________________________________________ 
Ø Are you aware that WHO guideline of cystic echinococcosis is available in your 
hospital? 
o Yes 
o No 
Ø [if YES to question 17] Which edition of WHO guideline of cystic echinococcosis is 
available in your hospital? 
o 1996 
o 2010 
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Manuscript to be submitted to Mongolian Medical Journal 
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7.1 What is One Health? 
 
A current definition of One Health is any added value, regarding health of humans 
and animals, financial savings or environmental services, which is achievable through 
a closer  cooperation of human and veterinary medicine when compared to the two 
medical sectors working alone (Chapter 2, (Zinsstag, 2015)). In other words, dialogue 
and closer cooperation between human and animal health sectors should lead to a 
synergistic effect. Earlier disease outbreaks characterized by misdiagnosis and/or 
delayed detection due to lack of communication between public and animal health 
sectors have been documented, for example Rift Valley fever in Mauritania (Digoutte, 
1999; Zinsstag et al., 2007) and Q-fever in the Netherlands (Enserink, 2010). Examples 
such as these were instrumental in conceptualizing modern One Health (Zinsstag et 
al., 2005b). The above mentioned added value of closer cooperation requires new 
methods for addressing the animal/human interface both qualitatively and 
quantitatively to demonstrate linkages between human and animal infections, joint 
estimations of the burden of disease, societal assessment of disease cost and financial 
savings of intervention and joint health services.  
 
7.2 Examples of One Health approach   
 
A simultaneous cross-sectional serological survey of brucellosis was conducted in 
human and livestock populations in Kyrgyzstan (Bonfoh et al., 2012).  Samples were 
collected from sheep, goats, cattle, and humans. Serological results were confirmed by 
molecular typing of bacterial isolates (Kasymbekov et al., 2013).  In this way, it could 
be shown that human brucellosis seropositivity depended mostly on sheep, which 
were identified as a main reservoir for brucellosis in Kyrgyzstan. Ironically, bacterial 
Brucella isolates from humans could not be investigated at the same time because the 
public health authorities would not agree to collaborate. This is a classic example of 
the need for building better communication between sectors beforehand. In the 
Kyrgyzstan study, an association between human and animal seroprevalence was 
found, but such relationships are not always demonstrated, as shown by a similar 
study on brucellosis in Mongolia (Tsend et al., 2014). Demonstrating linkages between 
human and animal disease frequencies depends, among other factors, on the 
geographical scale and the mobility of pastoral communities.  
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 	 The concept of added value of a One Health approach can be clearly shown using 
the example of economic analysis. Brucellosis, which causes abortion in animals and 
chronic febrile illness in humans, is one of the top priority zoonotic diseases in 
Mongolia. The financial aspect of a control strategy was assessed, using a One Health 
approach, to decide whether mass vaccination of 25 million cattle, goats and sheep 
was justified in order to prevent human brucellosis. Based on a dynamic livestock-
human brucellosis transmission model,  a cross-sector economic analysis estimated 
the public and private costs of health care for brucellosis  using statistical information 
and patient interviews (Zinsstag et al., 2005a). Expenditures on out-of-pocket 
expenses, transportation, drugs, and informal treatments were recognized as an 
inseparable aspect in estimating the societal cost since the patients are mostly from 
remote rural communities . The cost of livestock mass vaccination exceeded the 
benefits in public health, which would, from a public health perspective, lead to the 
conclusion that mass vaccination of livestock is not profitable. However, a subsequent 
cross-sector assessment included private health costs, out-of-pocket expenses and the 
benefits of reduced abortion to livestock production. The cumulative societal benefits 
of the livestock mass vaccination exceeded the cost of livestock mass vaccination by a 
factor of three. This example shows that when a sectoral view is extended to include 
a societal perspective, interventions which are not profitable for one sector may 
become profitable for the whole society. 
A further compelling example of One Health economics, which is directly 
analogous to echinococcosis, is dog transmitted rabies. Rabies is an invariably fatal 
viral disease, transmitted almost exclusively by animal bites. Humans do not 
contribute to rabies transmission dynamics, and the most common reservoir of rabies 
in developing countries is the domestic dog. Human post-exposure prophylaxis (PEP) 
is life-saving when instituted immediately after exposure to a rabid animal. However, 
this does not interrupt the transmission cycle in dogs, which can only be achieved 
through mass vaccination of dogs. Recent simulations and mass vaccination 
campaigns show that the cumulative cost of PEP continues to rise (Zinsstag et al., 2009; 
Mindekem et al., 2017) . In contrast, the cumulative cost of dog mass vaccination along 
with human PEP starts at a higher cost because of the cost of dog mass vaccination 
but reaches a plateau earlier because dog rabies transmission is interrupted. The 
cumulative cost of dog mass vaccination and PEP eventually breaks even with the 
cumulative cost of PEP alone. After that point, the cumulative cost of dog rabies mass 
vaccination is less than human PEP alone.  
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7.3 The key challenges for control of cystic echinococcosis in Mongolia 
 
Often the long-term control program interrupted mainly due to an financial problem. 
Despite the necessity for sustainable financial resources, a key problem in Mongolia 
is human resources. According to national statistics from 2014, a total of only 1609 
people worked in 921 private veterinary services in the country. One veterinarian was 
responsible for 29000 animals, on average. Given the current human resources, 
providing a dog deworming service over the vast territory of 1.5 million square 
kilometers with a density of 2 people per square km would require an enormous 
amount of time, in addition to the financial resources necessary for transport and 
accommodation. These unique conditions clearly show the challenges of CE control 
in the veterinary sector, especially in nomadic and semi-nomadic pastoral settings 
(Huang et al., 2008; Larrieu and Zanini, 2012). Figure 1 summarizes the important 
factors to consider in choosing effective and sustainable interventions for CE in 
Mongolia. The transmission cycle is between dogs and livestock, and potential control 
strategies could be employed at different stages including supervised dog deworming 
with praziquantel (PZQ), Eg95 vaccination of sheep, slaughterhouse management, 
and health education. For each of these interventions, there are several underlying 
questions which are absolutely critical for sustainability.  
On a global scale, a major question is the cost-effectiveness of Eg95 vaccination 
for sheep (Torgerson and Heath, 2003; Gauci et al., 2005; Larrieu et al., 2013). 
According to a recent trial in China and Argentina, the vaccine is highly effective 
against cystic echinococcosis caused by sheep strains.  Mongolia has over 60 million 
livestock animals, of which 20 million are sheep. This would lead to a high cost of 
vaccination. Disease understanding and awareness is still low in rural communities, 
and therefore the incentive to mobilize and vaccinate these animals is expected to be 
low. Advocacy of long-term benefit of the vaccines to authorities is essential. The 
question posed is: Is it less costly to treat humans infected with CE using 
chemotherapy and surgery, or is it, in the long run, less costly to deworm dogs and 
vaccinate livestock, with the aim of interrupting transmission? In addition, 
echinococcosis poses direct animal health losses to livestock (Torgerson, 2003). 
Livestock production loss estimated to be 10% or more and can cause substantial loss 
to agriculture. The benefit to both livestock health and human health should be 
accounted when estimating the cost-effectiveness. Also, the cost can be reduced by 
integrating Eg95 vaccination campaign with other national program that has the same  
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target groups. Mongolia is highly resource-limited country with a great geographical 
challenge. Therefore, adaptable, country-specific strategy to control CE is should be 
developed.   
 
 
Figure 1. Cystic echinococcosis transmission and intervention choice in Mongolia.  
 
7.4 Emergence of One Health in Mongolia and implication on CE 
 
Due to the frequent zoonotic outbreaks and natural disasters, the inter-sectoral 
communication was already built in the system.  The main organizations in that 
network are National Center for Communicable Disease (NCCD), and National 
Center for Zoonotic Disease (NCZD) and State Central Veterinary Laboratory (SCVL), 
Department of Veterinary and Animal Breeding Government Agency (AVSAB), 
Institute of Veterinary Medicine (IVM), and National Emergency Management 
Agency (NEMA). However, it mainly acted on the outbreaks or emergency.  
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 	 Official inter-sectoral committee for zoonotic and vector-borne disease was 
established between ministries during the “One Health-One World” project from 
World Bank which was mainly focused on Avian Influenza, and subsequent project 
from World Bank “Capacity building on prevention and control of infectious disease” 
(Figure 2). The latter one supported multiple inter-sectoral research of zoonotic 
disease including CE and was facilitating the collaboration between the sectors.  
 
Figure 2. The structure of the inter-sectoral committee. MoFA-Ministry if Food and 
Agriculture, NCIDNF is former name of National Center of Zoonotic Disease (2011). 
 
At the same time, the long-term inter-sectorial project “Animal Health” to improve 
intervention in brucellosis funded by Swiss Development Agency (SDA) continuously 
trained the mixed group of specialists from the organizations mentioned above. Also, 
the “Strengthen the control of vector-borne disease and lessen the impact of climate 
change” inter-sectoral project funded by Korean International Agency (KOICA) was 
ongoing. All these projects hugely contribute to forming the One-Health concept in 
Mongolia. Also, professional network becomes much stronger, and the understanding 
of the zoonotic disease became increased dramatically. In the outcome, government 
specialists raised the issue of investing the zoonotic diseases in Mongolia to WHO. At 
that time, there was no investment due to lack of evidence. However, this was the first 
step to get introduced to the Neglected Zoonotic Disease (NTD) framework from 
WHO. The national reports revealed that evidence of CE emergence in the country 
and addressed the need for further investigation. WHO in 2013, conducted situation 
analysis during the mission visit in Mongolia and the main conclusion is that there is 
great potential to be endemic and effort should be taken to improve surveillance in 
both sectors and clinical management(NTD/WHO, 2013).  
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8. Discussion 
 
Cystic echinococcosis (CE) is one of the neglected diseases in Mongolia. Although, the 
key components and infrastructure for surveillance and control of CE  exist within the 
human and animal health system (Figure 1), the period of critical shortcomings for the 
surveillance and control of many zoonotic disease occurred when the animal health 
sector was privatized after the end of the socialist period, at the beginning of the 1990s 
as a result of an abrupt political shift towards a liberal market reform and the 
reduction of state services (Ebright et al., 2003).  
CE is a disease that has multiple host species  requiring multiple sectors to 
collaborate for maintaining an adequate surveillance and response system. In the 
present work it was essential to establish a dialogue between the public and animal 
health sectors in the first place about this neglected disease. The magnitude of the 
problem was not visible due to lack of communication between and within the sectors, 
lack of technical knowledge, and complex ecology of transmission of the disease. 
Efforts were made by international scientists to discuss CE and specialists were 
trained for molecular analysis. Although it was an important step, the results from 
earlier studies  failed to be conveyed to the public health policy makers (Wang et al., 
2005; Gurbadam et al., 2010; Ito and Budke, 2015). While the true burden of the CE 
remains hidden under the “tip of the iceberg” cases, massive animal reservoirs 
continue to share the parasite load silently until the human cases reach epidemic 
proportions. For diseases with a long lag period, such as CE, waiting for the 
transmission  to be manifest in humans is too expensive, and makes disease control 
very difficult. Therefore, immediate actions need to be taken to reveal the true burden 
through improved surveillance systems in both the human and animal sectors while 
implementing an effective strategy for case management.  
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 Figure 1. Health system of Mongolia(Tsilaanjav et al., 2013). Aimag-Province; Soum-
subdivision of province; Bagh –smallest administrative unit. 
 
8.1 Key challenges 
 
8.1.1 Human CE 
Surveillance. Both surgical and non-surgical cases are not in the official reports. 
Active surveillance is currently not conducted. From the structure of the Mongolian 
Health system regarding passive CE  surveillance, it has almost full capacity to 
provide surveillance of CE (Figure 1).  However, we identified critical points that need 
to be communicated to facilitate smooth CE reporting. There is a good network of 
primary health care which is also supervised by secondary and tertiary hospitals and 
eventually belonging to the Ministry of Health (Figure 2).  
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*- smaller administrative unit of the province 
**- smaller administrative unit of the district 
Figure 2.  CE management provided at the three levels of health care in Mongolia.  
 
This is the main flow of the CE patient. In our data, very few cases cases  directly 
approach the tertiary hospital. This network is well communicated to the notifiable 
disease system,  organized by the National Centre for Communicable Diseases 
(NCCD) and the National Centre for Zoonotic Diseases (NCZD). But CE is considered 
as a chronic surgical disease and does not belong to notifiable disease registry while 
other zoonotic disease including brucellosis, rabies, tick-borne diseases are reported 
at the notifiable disease center (www.mohs.mn). The number of CE cases usually ends 
up to be reported together with other surgical diseases in the official reports.  
 
Clinical management. The inclusion of CE within the notifiable disease registry 
would not be successful without clear a case definition guided by the standard clinical 
guidelines. All diagnostics of abdominal lesions heavily rely on the radiologists, but 
not all CE cases are reported in the digital system due to the uncertainty of the case 
definition. Moreover, all treatment options recommended by WHO-Informal 
Working Group on Echinococcosis (WHO-IWGE) group except “watch & wait” is not 
available at the secondary level. There is no regular albendazole supply in the rural 
provinces, and its price is high.  CE surgery is  not conducted at the local level and 
only provided by the few surgeons in tertiary hospitals. Therefore,  patients diagnosed 
with  CE,  have  to   go  to  a  tertiary  center  in  Ulaanbaator to   receive  the  required  
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treatments, and they would not be hospitalized at the secondary level unless they 
were reported with another disease that the secondary level could provide service for. 
Such situations puts the radiologists, internists in a difficult situation to report CE, 
which causes so seldom to report CE in the statistical system of secondary level 
hospitals.   
CE is a highly local disease in Mongolia. Radiologists and surgeons, have 
extensively studied CE in the period of 1950-1980 to improve the clinical management. 
We found at least two local proposals for classification of echinococcosis in 1990 
(Sodov, 1990; Munkhtogoo, 1991). The pathognomonic features in ultrasound 
including “water-lily” shape, “honeycomb like” shape, or “umbrella” signs, were 
familiar, which was also listed in the Clinical Guideline for Diagnostics of Common 
Disease (MoH, 2008). However, it is still a grey area, especially for young radiologists. 
Current radiologists graduated from two distinct training systems: 1) the Medical 
School for specialization for radiology and 2) the  Mongolian Society of Diagnostic 
Ultrasound (MSDU) for primary and secondary health care specialists.  
 
8.1.2 Livestock CE 
The available data on the prevalence of CE in animals was too limited for a 
comprehensive assessment of the situation (NTD/WHO, 2013; Chinchuluun et al., 
2014; Yanagida et al., 2017). Public veterinary services inspect all animals that are 
brought to the public slaughter houses. However, there are only two major public 
slaughterhouses in Ulaanbaatar, and most of the slaughterhouses outside of 
Ulaanbaatar are privately owned.  Every branch office in the local province has a role 
to conduct  surveys, laboratory analyses and supervise local veterinarians, veterinary 
pharmacies, control vaccinations and dog deworming. The main challenge is that 
salaries of state veterinarians much lower than those of private veterinarians. This 
imbalance affects human resource of the public veterinarians, and the inspection 
activity of public veterinary sector is very much limited in the rural areas. 
 
8.1.3 Dog management 
There is no information of Echinococcus in dogs in Mongolia. It was not well decided 
whose responsibility it was to control and prevent the disease in dogs. A huge number 
of stray dogs are now in Ulaanbaatar city and rural areas. Usually, stray dogs are 
handled by the local governors. There are statistics of dog-owners in Ulaanbaatar city 
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but not in the rural areas. There was a long discussion between NCZD, Institute of 
Veterinary Medicine (IVM) and City Governors` office to establish a strategy to 
control and prevent diseases in dogs and cats. NCZD has more responsibility due to 
the experience in rabies (Bayar et al., 2016). However, experience on working dog feces 
surveys, parasitological examination, and conducting  laboratory analyses is hugely 
lacking. There is a huge shortage of parasitologists in all institutes. The laboratory 
capacity for both human and animal diagnosis is not yet well established. Safer 
techniques could be implemented to avoid exposure of laboratory personnel, for 
example, the Kato-Katz technique is used for the analysis of dog feces (NTD/WHO, 
2013). 
 
8.2 Research findings 
8.2.1 Human CE 
8.2.1.1 Burden 
Our estimate is the first comprehensive insight into the burden of disease of CE in 
Mongolia. All currently available data were attempted to be collected from different 
sources. Four available sources were scrutinized to estimate the burden: 1) Medical 
records of surgical patients at the major hospitals for 8 years; 2) Un-aggregated 
hospital discharge statistical information from the Department of Health 
Development in MoH for 11 years; 3) Digital records (Health-Info) system; 4) 
Ultrasound examination report from the secondary hospitals. The last two sources 
failed to give sufficient data. Therefore, we developed an online tool for clinicians to 
report the diagnosed cases and followed it for one year for the burden estimate.  There 
is a huge difference between the estimated number of surgical, non-surgical and 
undiagnosed cases. This is mainly caused by disease detection, reporting tool, 
geographical limitation in accessing health care and lack of disease knowledge in the 
population. In Mongolia, where exposure to an animal is high in the absence of control 
action, provision of epidemiological number can give the opportunity to compare and 
make decisions.    
 
Recommendations and further research: 
• Large scale community ultrasound surveys to validate the estimated 
burden. 
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 	 • Understanding of the difference between health seeking patients and 
non-seeking patients would be very useful factor for predicting the 
proportion of undiagnosed cases. 
• The inclusion of CE in the notifiable disease report after conducting the 
training on the CE staging described by WHO-IWGE and implement the 
case definition based on WHO-IWGE classification. 
• Surveys on the health status of people whose CE stage is known could 
provide valuable information to further assess the disability weight of CE.  
• High societal cost from CE is an important message to invest in the control 
and prevention strategy in cost-effective way. 
8.2.1.2 Cost 
We provide the first estimation of the societal cost of human CE in Mongolia. CE is a 
neglected disease that affects the marginalized population. The disease causes a 
significant amount of loss to society and household economy. Our results inform 
decision makers to further develop a strategy to control the disease and prevent the 
future cost of CE. The economic loss due to human CE was US$ 2.7 million when 
accounting the productivity loss, which is equal to 0.024% of the Gross Domestic 
Product (GDP) of Mongolia. This number is an underestimate because in Mongolia 
there is no animal prevalence data in livestock. The cost of diagnosed cases alone 
would be 0.3 million which is still a substantial number for only 476 patients. And yet, 
only 10% of it is supported by the government. Regarding out-of-pocket expenditure, 
76% of the total medical cost was borne by CE patients, while Dugee et al., (2018) 
reported 70% for patients in chronic disease which validates our estimation (Dugee et 
al., 2018). This is defined as catastrophic-out-of-pocket expense and a major public 
health issue in Mongolia at the moment(Dugee et al., 2017). Especially, the 
albendazole price for one pill is about two US$ dollar which is a high price. During 
the stakeholder meeting in 2016, we had the chance to talk shortly with a patient 
coming from Ovorkhangai province who had CE surgery one month ago. He just had 
finished taking one month of albendazole. He described his issue: “I had 40 sheep.  
Every time when I finish my drug, I was selling my sheep one by one. Now I have just a few 
sheep left. And when the sheep are finished, I will stop taking the drug”. Unsurprisingly, this 
situation reflects for many cases CE patients as the cost of albendazole is the highest 
proportion of the total cost after productivity loss.  
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 	 Recommendations and further research: 
• Measuring the animal productivity loss supported by the animal prevalence 
data. This would complete the estimation of full societal cost. 
• This was a first estimation on neglected zoonotic and parasitic disease in 
Mongolia. The burden of parasitic disease is very much neglected in Mongolia 
and we hope our estimate will raise the issue of re-surging the parasitic disease 
field in Mongolia. However, the parameters need to be improved in the next 
cost estimation. Including human productivity loss. 
• To our knowledge, prior to our work the cost of brucellosis was the first 
estimate for both the human and animal sectors conducted in Mongolia The 
cost of other zoonotic disease must be calculated in a similar way using all 
available data and should lead to policy recommendations for decision making 
on zoonoses control (Roth et al., 2003; Zinsstag et al., 2005a).  
• Loss of working time is high for both patients and caretakers. One of the 
solutions would be the implementation of telemedicine for CE referral or 
Percutaneous Treatment (PT) which requires  shorter stays in hospital than 
surgery. The possibility of implementation and training needs should be 
explored.  
 
8.2.1.3 Clinical management 
WHO-IWGE guidelines for allocating patients to the four treatment options based on 
CE cyst staging – are not implemented resulting in surgical treatment of all CE 
patients, in an unnecessary high-risk approach in patients who could be treated with 
albendazole, percutaneously or who could just be observed (watch and wait). Access 
to the privileged treatment centers, the three state hospitals, is limited by geographic 
distance and economic resources. The ultrasonography doctors in rural health centers 
play a pivotal role in clinical decision making. Ultrasonography is available, but 
unstandardized diagnostic approach and uncertainty of available treatment including 
albendazole in local hospitals are the main challenges, leading to a lack of diagnostic 
confidence. The majority (90%) of the clinicians at the secondary level did not know 
about the WHO-IWGE algorithm and all were willing to participate in the training 
program. 
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 	 Recommendations and further research: 
• To systematically include CE into the disease surveillance system of Mongolia 
• To make ultrasonography available to the primary / secondary health care 
level and to train local, rural physicians in the diagnostic features of CE and CE 
cyst staging. The Focused Assessment with Sonography for Echinococcosis 
(FASE), a short-term course for general practitioners, could be a 
model(Tamarozzi et al., 2014). In 2016, the pilot training was conducted to 
primary/secondary ultrasonography doctors on WHO-IWGE cyst staging by 
leading experts in the field ( 1) (Bold, 2016) (Appendix 2).   
• To introduce and implement the WHO-IWGE guidelines at all levels of the 
health care system to triage patients into the four WHO treatment modalities 
(a) medical treatment of small active cysts, (b) percutaneous treatment of larger 
active cysts (CE 1 and CE 3a), (c) surgery for complicated, very large cysts and 
cysts unresponsive to medical therapy, and (d) watch & wait for inactive cysts 
(CE4 and CE5) (Brunetti et al., 2010). 
 
8.2.2 Livestock CE 
New research questions arised while we were investigating the incidence data. The 
camel population was the only livestock species  having a statistically significant 
association with human cases of CE. Our study is the first report in Mongolia that 
gives insight into the prevalence of CE in the camels and goat, although the sample 
size, number of locations needs to be increased. An important finding in our study is 
that we identified the common haplotype of E. canadensis G6-7 in humans, camels, 
goat, and wolves in the same region, using the previously described genetic 
information of humans and wild canids. To our knowledge, this is the most 
comprehensive description of the current epidemiological situation of CE in Mongolia 
with substantial evidence of camel as an important intermediate host of E.canadensis 
in the country. Mongolia locates right between Central Asia, China, and Russia. 
However, the area was never explored enough regarding CE.  Our survey was a short 
survey of only one week from 1 province (Table 1). Yet, there are many interesting 
findings such as the first report of E.canadensis from a goat in Mongolia, first mixed 
infection from E.canadensis, two new haplotypes. There is a huge potential in Mongolia 
for further  studies in livestock. Specifically it is surprising that given the large 
numbers of sheep and goat, they don’t seem to play and important role as 
intermediary hosts?.  
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 	 Table 1.  Echinococcus spp. cases in different hosts in Mongolia 
Host G1 Reference G6-7 Reference G10 Ref. 
Human 46 
(Jabbar et al., 2011; 
Ito et al., 2014) 7 
(Jabbar et al., 2011; Ito 
et al., 2014) 5 
(Ito et al., 
2014) 
Dog  5 (Zhong et al., 2014)     
Fox   
 
3 
(Ito et al., 2013) 
2 
(Ito et al., 
2013) 
Wolf       
Goat    1 Current study    
Camel   
 
18 
Current study,  
(Yanagida et al., 2017)   
 
Sheep       
Cattle       
(review was updated from Deplazes et al., 2017);  
Recommendations and further research: 
• There is a huge research gap untouched in Mongolia concerning CE in the animal 
population. A main issue is the lack of access to private slaughterhouses. 
However, our study showed that in collaboration with a local veterinarians and 
nomadic farmers, a survey would be possible. 
• One Health study including multiple host animals in one space and time can give 
more accurate, faster, and more valid information regarding zoonotic linkage and 
create a clearly added value compared to separated sectoral studies (Zinsstag, 
2015). Further surveys should include larger samples involving more host 
animals. 
• This is the first report of CE prevalence in the animal population, which 
contributes to developing first transmission model for CE in Mongolia, including 
camels. 
• Our study could not have provided the same information without previously 
identified genetic information on humans. Therefore, further genetic studies of CE 
patients is encouraged. There is strong competition between the institutes and 
researchers on the genetic studies and they are reluctant to collaborate. This leads 
to a compromised comparability as we witnessed during our study. We realized 
that only a collaborative approach can facilitate systematic well-designed One 
Health sample collection and can provide more valuable information(Schelling, 
2015). 
• Protocols of CE sample collection should be standardized for both human and 
animal health sectors.    
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We provided the first estimate of the burden and cost due to CE in Mongolia and  
insight into the magnitude of the problem caused by CE in the society and the health 
system. Our statistical results on camel population and human incidence is a 
successful example of using already available data to show the zoonotic linkage 
despite the absence of public slaughterhouses and human resource. It provides a 
further case example for an added value of a closer cooperation between human and 
animal health (Zinsstag, 2015) There is a further added value of combining statistical 
data and genetic data. We also identified key challenges in clinical management. The 
challenges are solvable. The critical message in the clinical management is that the 
sequence of action should be 1) improve the supply of albendazole, 2)training  
ultrasound doctors on stage-specific treatment, 3) implementing the WHO based case 
definition and staging of cysts, 4)inclusion of CE in the notifiable disease. But not the 
other way around. Actions one and two can be implemented at the same time. This 
work is primarily to serve decision making of control and prevention of CE for human 
and animal health specialist in Mongolia. Two important lessons were learned during 
our study: 1) Studies on neglected zoonotic disease require special study designs for 
the provision of evidence of human-animal linkages. Therefore, study designs should 
be adapted to neglected zoonotic diseases; 2) Better communication, and building 
networks between all the stakeholders including national and international partners 
is the key to success.  
 
Better drug supply and better diagnosis and clinical management of human patients 
are certainly the first steps to better Echinococcosis control in Mongolia. Yet this 
should not be the end and further efforts should be made to control CE at the source 
keeping its potential elimination in mind. The control at the source should include 1) 
the systematic training and implementation of behavior change in slaughter practices 
to avoid feeding offal to dogs 2) The systematic deworming of dogs and safe disposal 
of dog feces during the period of worm excretion. 3) the testing of recently developed 
livestock vaccines in Mongolia. Specifically, it would be very interesting if the could 
also protect camels. 4) training and implementation of behavior change of hand 
hygiene would not only prevent exposure to CE but also other diseases. 5) All 
intervention studies should be accompanied by relevant follow up of intervention 
effectiveness and barriers of implementation. 
9. Conclusion and Outlook
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 	 Appendix 1 
 
Report of the stakeholder meeting “Multidisciplinary stakeholder meeting 
on the strengthening surveillance of cystic echinococcosis in Mongolia”, 
Ulaanbaatar, 16-17 September. 
 
Background 
Mongolia is one of the countries that have the highest risk of cystic echinococcosis 
(CE). This is because one third of the population is engaged in extensive pastoral sheep 
farming. The most vulnerable group for echinococcosis is likely to be herder 
communities who cannot afford the treatment and transport cost. An existing health 
service in Mongolia barely reaches the targeted population and cases are detected at 
a late stage. Due to the poor reporting system and late diagnosis, information 
regarding the epidemiology of echinococcosis is scarce. 
In 2013, WHO experts highly recommended to improve the surveillance system 
and case management for cystic echinococcosis during their mission in Mongolia to 
assess situation on echinococcosis. There are several individual studies conducted 
since 2013 to identify current prevalence, burden and cost of disease. Individual 
studies from different organizations need to be combined and compared. To 
implement the knowledge obtained from these studies, an engagement from the 
national decision makers is essential. The clinical management and possibility to 
optimize the clinical algorithm is in progress and will be the main evidence for 
developing Standard Operational Procedure for clinical management of CE. It is a key 
moment to update the current available information and discuss further plans. 
In collaboration with National Center of Zoonotic Disease (NCZD), and 
Mongolian Society of Diagnostic Ultrasonography (MSDU), we conducted two days 
of Stakeholder meetings on strengthening control and clinical management of cystic 
echinococcosis in Mongolia between 16-17, September 2016. All the stakeholders 
including representative from ministry of health, WHO country office, national 
centers, hospitals, academics who work on echinococcosis, ultrasonography doctors 
and epidemiologists from all of the provinces participated. The international leading 
experts on cystic echinococcosis participated in the meeting and gave insightful 
recommendations and lectures to the participants. 
 
Working group for the Stakeholders meeting 
A working group consisted of specialists from MSDU, NCZD, National Center for 
Communicable Diseases (NCCD). 
 
Stakeholders:  
Ministry of Health and Sport (MoHS), WHO, NCZD, NCCD, MSDU, Mongolian 
National Association of Surgeons (MNAS), Institute of Veterinary Medicine (IVM), 
Health Science University of Mongolia (HSUM) and provincial clinicians and 
epidemiologists.  
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 	 Facilitators: 
• Professor Sonin Sodov, The president of MSDU 
• Dr. Bolor Bold, researcher in NCZD 
• Dr. Erdenebileg Bavuujav, Ultrasound expert,  MSDU  
• Dr. Tsogbadralh Nyamkhuu, The director of NCZD 
The participants (70 people): 
International experts invited: 
• Dr. Bernadette Abela-Ridder, Team leader of Neglected Zoonotic Disease in 
WHO HQ 
     
 
• Prof. Thomas Junghanss, Chief of Section of Tropical Infectious Disease, 
Heidelberg University Hospital  
• Dr. Francesca Tamarozzi, Project manager of HERACLES (European cyst 
echinococcosis project) in University of Pavia, WHO collaborating center 
for CE 
• Prof. Ning Xiao, Deputy director of National Institute of Parasitic Diseases 
in Shnaghai, China CDC (NIPD)  
National participants: 
• Ultrasonography Specialists  
• Surgeons from central hospitals (First Central Hospital, Third hospital,  
National Center of  Maternal Child Health ) 
• 21 Clinicians from the provinces (General Hospitals) 
• 21 Epidemiologists from Province (Provincial Zoonotic Centers and General 
Hospitals) 
• Experts from NCZD, NCCD, IVM, HSUM 
Opening session: 
Dr. Narangerel, Officer in Charge of Emergency Operational Center in Ministry of 
Health opened the session with an high emphasis of CE an important issue especially 
for Mongolia because of people have high possibility to expose the infection. Dog 
deworming, educating of the population, and early detection are the key issues to be 
addressed to prevent from this disease. Rural, herder communities are exposed to the 
infection which often goes undetected with consequences of chronic, long-term illness 
that put them in high burden. She stressed the importance of timelines and 
collaborative effort of the meeting to control the disease. 
Dr. Soe Nyunt-U, WHO representative in Mongolia was very appreciative about the 
attention from both international and national experts on this disease and 
collaborating to strengthen the current clinical management and control activities. 
Currently, an on-going national programme organized by HSUM, with support of 
WHO  focuses  on  early  detection  of  all  adults  above 40 years old. The programme  
• Prof. Jakob Zinsstag, Head of Human and Animal Health unit, Swiss
 Tropical and Public Health Institute (Swiss TPH)
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started from the 3 soums of Omnogobi province, and will eventually cover all over 
Mongolia in coming three years. The main objective is to establish a database from the 
result of medical examination of all people, which could be further analysed by 
experts. The examination of ultrasonography can be shared with the experts on CE for 
to estimate prevalence of cystic echinococcosis. Since the start of the programme, 
increasing the technical knowledge of the remote doctors is very much needed and 
this meeting outcome will highly contribute to the primary health care doctors 
diagnosing and examining skills.  
 
Dr. Bernadette Abela-Ridder, Team Leader of Neglected Tropical Disease(NTD) 
unit in WHO in Geneva, highlighted the previous mission in 2013 on cystic 
echinococcosis and appreciated the progress until 2016. She gave an overview of 
WHO strategy, vision on NTD and how echinococcosis is inclusive within it. The 
participation of the countries is very important in achieving the goal on NTD by 2020. 
Just few months ago the WHO initiated the Working group on clinical management 
and Prof. Thomas Junghanss is the head of the working group, which also joined this 
stakeholder meeting. Therefore, it is a great opportunity to learn and experience from 
the national experts about the challenge and problems in control and clinical 
management of cystic echinococcosis. 
 
Dr. Enkhbayar, Secretary of Mongolian Society of Diagnostic Ultrasound 
mentioned working on CE project a year ago with Dr. Bolor Bold. Specialized 
diagnostic and therapeutic skill is in high level in most tertiary hospitals. Futher 
progress working with the NCZD on CE in the remote areas is planned. He 
emphasized international expert contributions to strengthening the clinical 
management of CE in Mongolia. The very fruitful symposium and hands-on training 
was held on 15 September on WHO-IWGE guideline of diagnosing CE and stage 
specific treatment organized in First Central Hospital with clinicians and Prof. 
Junghanss and Dr. Tamarozzi  lecturing on this subject.  
 
Discussions 
Prof. Thomas Junghanss from Heidelberg University, Dr. Francesca Tamarozzi from 
University of Pavia, Dr. Bernadette Abela Ridder a from WHO, Prof. Xiao Ning from 
Shanghai Parasitological Institute, Prof. Jakob Zinsstag from Swiss Tropical and 
Public Health Institute was invited and gave excellent presentations about current 
global vision on control of echinococcosis, implementation of classification system 
from WHO and stage-specific treatment. One of the issues stressed during the meeting 
was that of insufficient drug distribution. Currently albendazole is not supported by 
the insurance system. The rough estimate of price of albendazole for monthly usage 
equals the minimum wage of the country. This has a much bigger effect on the rural 
people, most of whom hardly have any income.       
In 2013, there was an initiation from the Mongolian government and a study 
was conducted on the epidemiology of echinococcosis. Lack of statistical information 
and no clinical registration at the provincial level was identified. As a tip of the 
iceberg- few  surgical  cases in  the  central  hospital  which  was about 30-40 in a year 
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 were reviewed. Among them young children have a high percentage. Preliminary 
estimate showed that at least 5 times higher cases diagnosed as CE in the province 
after reviewing documents in some provinces. There was absolutely no information 
about how many patients are infected in the population.   
There was small scale focus group discussion and health professional 
questionnaire on current clinical guidelines. Currently there is no guideline to 
diagnose in both central and primary health care. Diagnostic algorithm was last 
updated in 1987. Health professionals do not follow the classification system. Stage-
specific –treatment options were not discussed. Patients buy the anti-helminthic drug 
themselves, which is quite expensive. Technical capacity to conduct CE surgery is very 
limited in the provincial hospital. A majority of the patients were referred to the 
central hospital. The CE registration system has conflicts with the health insurance 
regulation, and therefore statistics are poorly recorded.  
We conducted a workshop in 2015 with ultrasonography doctors and 
epidemiologists from secondary hospitals in the provinces. One of the main objectives 
of the workshop was to introduce WHO- Informal Working Group Experts Consensus 
(WHO-IWGE) on classification of CE in ultrasonography. During the workshop, 
almost all the health professionals answered that they were not aware of the WHO-
IWGE classification system.  
A hands-on training program for central clinical professionals and provincial 
clinical professionals on using WHO classification system for diagnosing cystic 
echinococcosis by ultrasonography. We invited Prof. Thomas Junghanss and Dr. 
Francesca Tamarozzi to give a lecture on using a WHO-IWGE and stage specific 
treatment algorithm. The training was highly informative and efficient for the local 
participants.  
 
Experts recommandations 
Dr. Bernadette Abela-Ridder: 
• Encouraged  integration of control of cystic echinococcosis into the national health 
system 
• Further activities on control action should be focused on reducing risk factors 
Prof. Thomas Junghanss: 
In terms of optimizing clinical management, the following areas should have priority: 
• Early detection 
• Clinical management of detected patients. How to report to the system 
• Monitoring of the patients in primary, secondary, tertiary level 
• Defining the monitoring period 
• Integration into the health system 
Dr. Francesca Tamarozzi: 
• Surgical patients from rural areas are better able to be monitored in the provincial 
hospitals 
• E-registration form for reporting cases is more efficient when there are fewer, but 
more important questions.  
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Prof. Jakob Zinsstag: 
Further research on primary prevention is an essential part of control. The 
applicability of any prevention method should be considered in the Mongolian 
situation. Pilot project should be started on the primary preventive activities:  
• Educating people on cooking the dog food before feeding,  
• Dog deworming activities in collaboration with different sectors,  
• Vaccination of the intermediate host,  
• Integration of health system and other programme.   
Prof. Ning Xiao: Careful design of projects is crucial for the successful 
implementation. Especially, all the activities should be conducted in a best 
applicable way for Mongolia. 
• Health system strengthening  is the foundation 
• Criteria for surveillance system needs to be created 
• Baseline research on echinococcosis in national level is important for control strategy.  
• But before that small scale pilot study must be held in order to get an efficient result. 
Summary of the group work presented by Dr. Buyanjargal, vice director from 
NCCD. 
Ø On developing the guidelines of clinical management and surveillance of cystic 
echinococcosis based on WHO recommendation, following issues should be 
prioritized: 
o Primary prevention 
o Seasonal monitoring 
o Health professionals role should be defined clearly 
o Monitoring the patients at least 5 years after surgery 
Ø Implementation should be in alliance with other programmes in Mongolian 
health system 
Ø Indicators for programme implementation, baseline surveys needed to 
initiated.  
Ø Strengthening database, improve the surveillance system 
Ø Developing data registration form 
Ø Training on the approved guideline 
Ø Cost analysis to estimate burden  
Ø Discounting the drug price 
Ø Provision of drug and procurements 
Ø Strengthening the collaborating between different sectors 
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Figure 1. Stakeholder meeting participants. 
 
 
The list of the participants from the provincial centers for Stakeholders consultation meeting on the Control 
and Prevention of  Cystic Echinococcosis in Mongolia 
September 16-17, Corporate Convention Centre, Ulaanbaatar city      
№ Province/City Name Organization Occupation 
1 Arkhangai B.Byambasuren  Center of Zoonotic Disease epidemiologist 
2 Arkhangai B.Delgerkhangai  General Hospital US doctor 
3 Bayankhongor S.Baasankhuu Center of Zoonotic Disease epidemiologist 
4 Bayankhongor CH.Bayanmonkh General Hospital US doctor 
5 Govi-Altai S.Batsaikhan Center of Zoonotic Disease epidemiologist 
6 Govi-Altai TS.Sansarmaa General Hospital US doctor 
7 Darkhan-Uul L.Olziijragal Health Department epidemiologist 
8 Darkhan-Uul Z.Monkhsuvd General Hospital US doctor 
9 Dornogovi J.Myagmarsuren General Hospital epidemiologist 
10 Dornogovi U.Enkhbayar General Hospital US doctor 
11 Dundgovi B.Altantogs Center of Zoonotic Disease epidemiologist 
12 Dundgovi Buyandelger General Hospital US doctor 
13 Dornod Ch.Odgerel Health Department epidemiologist 
14 Dornod S.Yundendorj  General Hospital US doctor 
15 Sukhbaatar D.Oyunbileg Health Department epidemiologist 
16 Sukhbaatar Ts.Uuganmonkh General Hospital US doctor 
17 Khentii G.Gantsetseg Center of Zoonotic Disease epidemiologist 
18 Khentii Ya.Aюush Soum clinic US doctor 
19 Bayan-Olgii J.Balshikyer  Center of Zoonotic Disease epidemiologist 
20 Bayan-Olgii A.Akjarkhin General Hospital US doctor 
21 Zavkhan G.Dashdavaa Center of Zoonotic Disease epidemiologist 
22 Zavkhan B.Amarzayaa General Hospital US doctor 
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23 KHovd J.Mongontsetseg Center of Zoonotic Disease epidemiologist 
24 KHovd D.Sarangerel General Hospital US doctor 
25 Uvs G.Maralmaa Center of Zoonotic Disease epidemiologist 
26 Uvs P.Naranchimeg General Hospital US doctor 
27 Omnogovi Uuganjavkhaa Center of Zoonotic Disease epidemiologist 
28 Omnogovi L.Myaasuren  General Hospital US doctor 
29 Ovorkhangai S.KHorolmaa Center of Zoonotic Disease epidemiologist 
30 Ovorkhangai V.TSerendemberel General Hospital US doctor 
31 Bulgan S.Ariunaa Health Department epidemiologist 
32 Bulgan O.Bilguun General Hospital US doctor 
33 KHovsgol D.ErdeGHchimeg Center of Zoonotic Disease epidemiologist 
34 KHovsgol TS.ErdeGHbolor  General Hospital US doctor 
35 Selenge E.Saranzayaa Center of Zoonotic Disease epidemiologist 
36 Selenge J.Batsuren General Hospital US doctor 
37 Orkhon M.Uranchimeg General Hospital epidemiologist 
38 Orkhon TS.Mendsaikhan General Hospital US doctor 
39 Tov CH.Purevsuren Health Department epidemiologist 
40 Tov T.Amarsanaa General Hospital US doctor 
41 Govisumber SH.Altantsetseg Health Department epidemiologist 
42 Govisumber A.Oюuntsetseg General Hospital US doctor 
43 Niislel D. TSegmid Center of Zoonotic Disease epidemiologist 
44 Niislel G.Odontuul General Hospital US doctor 
 
 
 
The list of the speakers and national/international experts for Stakeholders consultation meeting on the 
Control and Prevention of  Cystic Echinococcosis in Mongolia 
 
September 16-17, Corporate Convention Centre, Ulaanbaatar city   
 
№ Name  Organization Occupation  Resp. 
1 D.Narangerel Ministry of Health Head of Emergency 
Operation Center 
Chairman/ 
Speaker 
2 N.Tsogbadrakh National Center of Zoonotic Disease 
(NCZD) 
Director Chairman/ 
Speaker 
3 S.Sonin Mongolian Society of Diagnostic 
Ultrasonography (MSDU) 
President Chairman/ 
Speaker 
4 Ya.Buyanjargal  National Center for Communicable 
Disease (NCCD) 
Deputy Director  Chairman/ 
Speaker 
5 D.Enkhbayar Mongolian Society of Diagnostic 
Ultrasonography (MSDU) 
Secretary Chairman/ 
Speaker 
6 Dr.Soe Nyunt-U World Health Organization, 
Country Office 
Representative Chairman/ 
Speaker 
7 O.Ariuntuya  World Health Organization, 
Country Office 
Officer  Participant 
8 A.Dolgorhand Ministry of Health Officer in Emergency 
Operation Center 
Participant 
9 D.Abmed National Center for Communicable 
Disease (NCCD) 
Senior consultant of 
parasitological 
Participant 
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laboratory, Head of 
Research Committee 
10 A.Ambaselmaa National Center for Communicable 
Disease (NCCD) 
Head of 
Communicable 
Disease Surveillance 
Department  
Participant 
11 Ts.Selenge  National Center for Communicable 
Disease (NCCD) 
Head of Zoonotic and 
Emerging Disease 
Surveillance Unit 
Participant 
12 M.Narankhajid Health Science University of 
Mongolia 
Lecturer in 
Parasitological 
Department  
Participant 
13 B.Boldbaatar  Institute of Veterinary Medicine, 
IVM 
Head of Virological 
Department 
Participant 
14 J.Erdenebaatar  Institute of Veterinary Medicine, 
IVM 
Head of Infectious 
disease and 
Immunological 
laboratory  
Participant 
15 Ya.Nomkhon State Department of Veterinary 
Medicine 
Senior consultant 
  
Participant 
16 D.Tserennorov  National Center of Zoonotic Disease 
(NCZD) 
Head of 
Administrative Unit 
Chairman/Speaker 
17 D.Ganbold  National Center of Zoonotic Disease 
(NCZD) 
Head of Professional 
Service Unit  
Participant 
18 N.Uranshagai National Center of Zoonotic Disease 
(NCZD) 
Researcher Coordinator 
19 Sh.Agiimaa National Center of Zoonotic Disease 
(NCZD) 
Officer in Charge of 
Echinococcosis in 
Surveillance 
Department 
Coordinator 
20 Ts.Bayar National Center of Zoonotic Disease 
(NCZD) 
Biologist and 
researcher in 
Surveillance 
Department 
Presenter 
21 B.Bolor  National Center of Zoonotic Disease 
(NCZD) 
Swiss Tropical and Public Health 
Institute 
Researcher and PhD 
candidate 
Coordinator 
22 D.Amgalan First Central Hospital of Mongolia Head of General 
Surgical Department 
Chairman/Speaker 
23 B.Chinchuluun Institute of Veterinary Medicine, 
IVM 
Researcher in 
Helminthology 
Laboratory  
Presenter 
24 D.Temuulen Health Science University of 
Mongolia 
Lecturer in 
Parasitological 
Department  
Presenter 
25 Ts.Lkhagvatsere
n 
Institute of Veterinary Medicine, 
IVM 
Researcher in 
Helminthology 
Laboratory  
Presenter 
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 	 Timetable for Multidisciplinary Stakeholder 
 Meeting on Strengthening 
The Control and Clinical Practice of Cystic Echinococcosis in 
Mongolia 
    
 3rd National Meeting on Neglected Zoonotic Diseases (NZDs) 
 
Day 1 Timetable       16.09.2016, Ulaanbaatar  
 
8.30-9.00 Registration 
9.00-9.30 
Opening remark 
MoH, 
WHO Representative in Mongolia 
Bernadette Abela-Ridder, Team Leader of Neglected Zoonotic Diseases, WHO 
Prof.Sonin Sodov, President of Mongolian Society of Diagnostic Ultrasound 
N.Tsogbadrakh, National Center for Zoonotic Disease 
9.30-12.30. Session 1. Strengthening the Surveillance System and Clinical 
Management of Cystic Echinococcosis (CE) in Mongolia: Challenges and 
Possibilities 
Chairperson: Dr.Narangerel D, Head of Emergency Operational Disease,, Ministry of Health 
9.30-10.00 
Current Situation of Cystic Echinococcosis in Mongolia 
Dr.Tsogbadrakh Nyamdorj, Director of National Center for Zoonotic Diseases 
10.00-
10.20 
WHO response on the Global Challenges of Cystic Echinococcosis 
Dr.Bernadette Abela-Ridder, Team Leader of  Neglected Zoonotic Diseases, 
NTD/WHO, Geneva, Switzerland 
10.20-
10.50 
Implementing One Health: Theory to Practice and Added Value 
Prof.Jakob Zinsstag, Head of Human and Animal Health Unit, Swiss Tropical 
and Public Health Institute (Swiss TPH), Basel, Switzerland 
10.50-
11.20 
Surveillance System of Echinococcosis in China 
Prof. Ning Xiao, Deputy Director, National Institute of Parasitic Diseases 
(NIPD), Shanghai, China  
11.20-
11.40 Tea break 
11.40-
12.00 
Current Epidemiological Burden and Societal Cost of Cystic 
Echinococcosis in Mongolia 
Bolor Bold, PhD candidate of Swiss Tropical and Public Health Institute (Swiss 
TPH), Basel, Switzerland 
12.00-
12.30 Discussion 
12.30-
13.30 
Lunch 
 
13.30-17.00. Session 2. Current Knowledge: The Update from the Recent Researches 
on CE in Mongolia 
Chairperson: Prof.Tsogbadrakh, Director of National Center for Zoonotic Diseases 
13.30-
13.45 
Molecular Genetical Study of Cystic Echinococcosis 
Dr.Temuulen Dorjsuren, Lecturer, Department of Parasitology, Health Science 
University of Mongolia 
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13.45-
14.00 
Serological Study of Cystic Echinococcosis in Human 
Dr. Anu, Researcher, Department of Parasitology, National Center for 
Communicable Diseases 
14.00-
14.15 
Echinococcosis Situation in Livestock Population and Challenges 
Dr. Chinchuluun Batbaatar, Researcher, Parasitological Department, National 
Institute of Veterinary Medicine 
14.15-
14.30 
Dog Survey in a Sub-Urban District of Ulaanbaatar 
Bayar Tserendovdon, Biologist, Surveillance Department, National Center for 
Zoonotic Diseases 
14.30-
15.00 
Validation of Molecular Genetic Studies of Cystic Echinococcosis  
Prof. Ning Xiao, Deputy Director, National Institute of Parasitic Diseases 
(NIPD), Shanghai, China 
15.00-
15.30 Discussion 
15.30-
15.50 Tea break 
15.50-
16.40 
Group work ( Part 1): Towards Integrated Human and Animal Cystic 
Echinococcosis (CE) Surveillance-and Control (elimination) in 
Mongolia 
16.40-
17.00 Presentation of group work 
 
Day 2 Timetable       17.09.2016, Ulaanbaatar  
 
8.30-9.00
  
Registration 
9.00-9.30 Summary of sessions on Day 1 
Bolor Bold, PhD candidate of Swiss Tropical and Public Health Institute 
(Swiss TPH), Basel, Switzerland 
9.30-12.30. Session 1. Strengthening the Surveillance System and Clinical 
Management of Cystic Echinococcosis (CE) in Mongolia: Further Strategy 
Chairperson: Dr. Enkhbayar Dondog, General Secretary of Mongolian Society of 
Diagnostic     Ultrasound 
9.30-10.20 Clinical management of CE patients: current guidelines and ways 
forward 
 Prof.Thomas Junghanss, Head of the Section of Tropical Medicine, 
University Hospital of Heidelberg, Germany 
10.20-
11.10 
WHO collaborating center of CE in Italy: Training on WHO 
classification system and introduction of European registry system 
of CE 
Dr. Francesca Tamarozzi, Project Coordinator, WHO collaborating center 
on CE, University of Pavia, Italy 
11.10-
11.20 Tea break 
11.20-
11.40 
Implementing the Algorithm for Clinical Management of CE: 
Feasibility of stage Specific Treatment 
Dr.L.Amgalan, Head of Surgical Department, First State Central Hospital 
!" #
 	
11.40-
12.00 
The Role of using WHO classification System for CE for Integrated 
Surveillance/Registration 
Prof. Sonin Sodov, President of Mongolian Society of Diagnostic Ultrasound 
Dr. Enkhbayar Dondog, General Secretary of Mongolian Society of 
Diagnostic Ultrasound 
12.00-
12.30 Discussion 
12.30-
13.30 Lunch 
13.30-17.00. Session 2. Discussion on the Standard Operational Procedure of 
Clinical Management and Surveillance 
Chairperson: Dr. Buyanjargal, Deputy Director of National Center for Communicable 
Diseases 
13.30-
13.45 
Introduction of the Draft of Guideline for Clinical Management 
and Surveillance for CE 
Bolor Bold, PhD candidate of Swiss Tropical and Public Health Institute 
13.45-
14.00 
Introduction of the Draft of Guideline for Surveillance for CE in 
Livestock 
Dr. Chinchuluun Batbaatar, Researcher, Parasitological Department, 
National Institute of Veterinary Medicine 
14.00-
14.30 Discussion 
14.30-
14.40 Tea break 
14.40-
15.50 
Group work ( Part 2): Towards Integrated Human and Animal CE 
Surveillance-and Control (elimination) in Mongolia 
15.50-
16.20 Presentation of group work 
16.20-
16.40 Summary and Closing 
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 	 Appendix 2 
 
Report of the training on clinical management of cystic echinococcosis in 
First Central Hospital of Ulaanbaatar city and Dalanzadgad hospital, 
Omnogobi province 
 
Background 
Cystic echinococcosis (CE) is caused by Echinococcosis granulosis (E.granulosis) an 
important zoonotic disease in Mongolia which has been endemic since the early 20th 
century. An intensive control program was implemented before the 1990s. During that 
period many improvements in the clinical management came about and 
echinococcosis was a notable topic in the surgical field. Innovative new techniques on 
CE surgical procedures for complicated case with variously-affected organs were 
introduced between 1960 and 1990. Worldwide, surgery was the only treatment 
available until the 1980s. In some countries, in the early 1980s less invasive or non-
invasive treatment options were applied in clinics, including benzimidazole and 
percutaneous treatment. The choice for optimal therapeutic approaches depends 
highly on the staging method of CE. In 1981, Gharbi et al., developed the staging 
system which is most widely used worldwide. In Mongolia Dr.Sonin Sodov applied 
it for the first time in the field of radiology. However, the therapeutic methods 
improved and there was a need to update CE staging. In 2011 the WHO-Informal 
Working Group on Echinococcosis (WHO-IWGE) developed an expert consensus for 
diagnosing CE. Based on the cyst staging protocol by WHO-IWGE, stage-specific 
treatment options could be chosen. In Mongolia, the WHO-IWGE guidelines are not 
yet implemented. The staging of hydatid cysts is not standardized and even often 
neglected in clinical practice.  Training is highly needed for local health professionals 
on the current standard clinical approach.  
 
Objective 
To pilot the training for the local specialists on CE diagnostics  
 
The working group:  
  
 
 
• Prof. Sonin Sodov, President of Mongolia Society of Diagnostic Ultrasound 
(MSDU); 
• Dr.Amgalan Luvsanjav, Head of General Surgical Department in First Central 
Hospital (FCH) 
• Dr. Erdenebileg Bavuujav, Secretary of Mongolia Society of Diagnostic 
Ultrasound and Senior (MSDU); Consultant of First Central Hospital (FCH) of 
Radiology  
• Dr. Tsogbadrakh Nyamdorj, Director of National Center of Zoonotic Disease 
(NCZD) 
• Bolor Bold, PhD Candidate University of Basel; Swiss Tropical and Public
 Health Institute (Swiss TPH); National Center for Zoonotic Diseases, Mongolia
 (NCZD)
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 	 • Dr.Agiimaa Shagj, Epidemiologist from National Center of Zoonotic Disease 
(NCZD) 
• Dr. Altanchimeg, Director of Center of Zoonotic Disease in Omnogobi 
Province (CZD) 
For the preparation of workshop, the working group met three times. To introduce 
the training objective, the role of each member was discussed. The training was 
organized twice: 
• The Symposium of Cystic Echinococcosis and Hands-on training on 15 
September in Ulaanbaatar in FCH with doctors, surgeons and district 
clinicians, radiologist.  
• Hands-on training of WHO-IWGE  classification and control on 18- 19 of 
September in Dalanzadgad city of Omnogobi province with local clinicians, 
radiologists and family doctors from 20 soums.  
 
The speakers and mentors for the workshop on CE clinical management are: 
• Dr.Francesca Tamarozzi, Project Manager of HERACLES (European Registry 
of Echinococcosis); Supervisor in FASE (Focused Assessment of Sonography 
for Echinococcosis) training in WHO-Collaborating Center in University of 
Pavia, Italy 
• Prof.Thomas Junghanss, Head of Tropical Medicine Section in Heidelbeg 
University Hospital, Heidelberg, Germany 
• Prof. Sonin Sodov, President of Mongolia Society of Diagnostic Ultrasound 
(MSDU), Ulaanbaatar Mongolia 
• Dr. Erdenebileg Bavuujav, Secretary of Mongolia Society of Diagnostic 
Ultrasound and Senior (MSDU); Consultant of First Central Hospital (FCH) 
of Radiology, Ulaanbaatar Mongolia 
• Dr.Amgalan Luvsanjav, Head of General Surgical Department in First 
Central Hospital (FCH), Ulaanbaatar Mongolia 
The speakers and mentors for the control: 
• Ning Xiao, Deputy director of National Institute of Parasitic Disease, 
Shanghai, China 
• Bernadette Abela Ridder, Team leader of Neglected Zoonotic Disease, NTD 
WHO HQ, Geneva, Switzerland 
  
• Chinchuluun Boldbaatar, Institute of Veterinary Medicine, Ulaanbaatar, 
Mongolia 
 
 
 
 
 
 
 
 
• Bolor Bold, University of Basel, Swiss TPH
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 	 September 15, 2016:  
The Symposium of Cystic Echinococcosis and Hands-on training in Ulaanbaatar in 
First Central Hospital, Ulaanbaatar 
 
Opening 
The first day of the workshop was conducted among clinicians of tertiary and 
secondary hospitals in FCH, Ulaanbaatar on 15 of September. The seminar was 
organized in alliance with fourth national symposium of MSDU in the theme of 
current liver diagnostic approaches. In the full day seminar clinicians from FCH, 
clinicians from district hospitals, general hospitals, and private hospitals participated. 
A total of 87 clinicians and specialists participated in the workshop. Prof.Byambadorj, 
the director of the FCH, and Prof. Sonin Sodov opened the workshop with 
presentations about the current importance of CE in Mongolia. Prof. Sonin 
emphasized that standardizing current clinical practice is one of the issues that has 
not been addressed for many years in Mongolia.  
 
Presentation from Prof. Sonin Sodov 
The first presentation was the diagnostic algorithm developed by Prof. Sonin on CE 
in 1987. It is based on the Gharbi et al., (1981) classification of diagnosing hydatid cyst 
using ultrasonography. Prof. Sonin was the first to introduce an ultrasonography 
machine in Mongolia in 1982, an ALOKA  SSD 202, and started to use it in FCH 
(formerly named as The State Central Clinical Hospital). Ultrasonography (US) is a 
first choice, most accurate diagnostic method. US images are direct visualization of 
the cyst including: size, location, vascular relations, number of cysts and other 
associated pathology. It is the least invasive, highly economic and most accessible in 
remote areas. Prof. Sonin talked about how prevalent CE was in Mongolia before 
1990s: “…There were no week without CE surgery in FCH…”.  
The previous classification, proposed by Prof. Sonin in 1987, is the following: 
Simple hydatid cyst ( wall- sign ) 
Hydatid cyst with daughter cyst – cysts within the cyst and honeycomb sign 
Dead hydatid cyst with daughter cyst-pattern and cyst within the cyst 
Dead hydatid cyst- pattern 
Partly calcified- striped 
Fully calcified- umbrella  
 
Presentation from Dr. Amgalan Luvsanjav 
Dr. Amgalan presented the historical development in CE surgical methods in 
Mongolia. CE was always one of the most challenging and interesting diseases in the 
surgical field in Mongolia, given the fact that it was one of the most common diseases. 
The leading clinical professors, including Prof. Dolgor, Prof. Ichinkhorloo, Prof. 
Davaatseren, were the pioneers in this field. Novel techniques in CE surgery have 
been patented with their names and implemented until now.  
 
Presentation from Dr. Francesca Tamarozzi 
After the Mongolian experts discussed current clinical management of CE, invited 
international experts gave presentations on clinical management of CE. Dr. Francesca 
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Tamarozzi from the WHO collaborating center at the University of Pavia presented 
the current diagnostic classification of CE recommended from WHO which was 
updated in 2011. The classification was standardized by WHO experts in 1995, in a 
form that could be applied in all settings to replace numerous previous classifications 
and allow a natural grouping of the cysts into three relevant groups:  
• active (CE1 and 2),  
• transitional (CE3) 
• inactive (CE4 and 5)   
 
Figure 1. WHO-IWGE classification of ultrasound imagec of cystic 
echinococcocosis cysts  (Brunetti et al., 2010)(WHO-IWGE, 2011). 
 
CL= Undifferentiated cysts. If the cyst was parasitic or non-parasitic is unknown. 
CE1= Active stage, unilocular, fluid filled cyst with “double line sign” 
CE2= Active stage, multiple daughter cysts, multiple septae resembles “honey comb”  
CE3A= Transitional ( active to inactive), filled with fluid and detachment of inner 
membranes resembles “water-lily-sign”. 
CE3B= Transitional ( inactive to active) , viability of parasite still remains, unilocular), 
composition of solid and daughter cysts.  
CE4= Inactive stage, different pattern of solid components, non-viable, pathognomonic 
channel-like pattern is seen.  
CE5= Inactive, thic cystic wall, and non-viable solid cystic appearance.  
 
This classification was updated in 2001 and again updated in 2011, with Type 3 further 
divided into two subgroups (CE3a- separated endocysts and CE3b- solid type 
containing daughter vesicle). In addition, all undifferentiated cysts can be classified 
into CL. Currently, the classification developed by Informal Working Group on 
Echinococcpsis from WHO (WHO-IWGE) in 2011 is the most recommended. Figure 1 
shows the classification algorithm updated by WHO-IWGE classification in 2011. 
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 	 Figure 2 presents the comparison between Gharbi and WHO-IWGE  
classification. Figure 2. Comparison of Gharbi’s and WHO-IWGE ultrasound 
classification(Brunetti et al., 2010). (WHO-IWGE, 2011). 
 
CL, as a potentially parasitic cyst, was not included in  Gharbi’s classification. WHO 
CE3b was not explicitly described by Gharbi. CE3b might be classified as Type III, 
although in the original Gharbi paper there was no distinction between 
multivesiculated (honeycomb-like) cysts and cysts with daughter cysts in solid 
matrix. 
Improvement in the updated classification (WHO-IWGE 2011) 
The hydatid cyst should transform into an inactive state at the end of its biological 
developement and die. Then biological sequence is the following:  
• Formation of active stage with filled with clear fluid (CE1)à 
• Gradually detachment of endocyst wall (CE3а) à 
• Most of the parasitic fluid is absorbed and only solid parts will be left 
(CE4) à 
• Inactive calcified, solid cyst (CE5).  
The patients were followed-up for 2 years without any intervention and 20% of them 
had recovered in a natural process.  
Natural detachment of endocyst wall (CE3a) can be interrupted by formation of 
multiple daughter cyst with septae, filled with highly infective parasitic fluid. In this 
case cyst is classified as CE2. The reason for CE1 to CE2 transition is not fully 
understood. However, host immune condition, number and infectivity of pathogen 
could influence the detachment of endocyst wall. The main reason for re-activation, 
classifiied as CE3b, is as a result of unsuccessful drug (albendazole) treatment.  
Albendazole can be prescribed in CE1, CE2, CE3a, CE3b stages of hydatid cyst with 
the single goal to progress the biological stage to CE4.  
If patient is diagnosed at the CE4 stage in the first visit, the probability of  inactivation 
of the cyst is very high. By follow-up study with CE4 patients, only 2% relapsed after 
5 years. Therefore, when patients diagnosed with CE4 at the first visit, monitoring 
without any other management should be sufficient for recovery. However, if the 
patient  transformed  into  CE4  in  the  result  of  albendazole  treatment,  around 50%  
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transform back to active stages because the viability of the parasite still remains and 
some daughter cysts re-formed with fluid. In the result, multiple daughter cysts with 
fluid are shown in a solid environment. Once the CE3b formed, the effect of 
albendazole decreases dramatically.   
 
The difference between CE3a and CE3b were studied in terms of viablitiy. Direct 
assessment of E. granulosus and its viability (Microscope examination of protoscoleces 
after cyst fluid aspiration using vital staining) gives evidence for the parasitic nature 
and viability of a cyst (WHO/OIE, 2001). In Table 1, the comparison between stages 
daignosed by US and actual biological viability stages are shown. Among all samples 
taken during the CE3a stage, 42% were viable by light microscopy and 35% by MR 
scpetroscopy. Among all samples taken during CE3b, 88% were viable. The result 
confirms that there is a principle difference between these stages and treatment 
decisions have to be taken into account differently. The Gharbi and other classification 
did not account for this difference, and were, therefore, not optimal for determining 
the best treatment option. 
 
Dr.Tamarozzi gave scietific evidence for each classification. For example since the 
earlier version of the CE classification, anti-helminthic treatment became an efficient 
non-invasive method for CE patient. Some major studies showed that 1-2 years after 
starting albendazole  treatment, 50-75% of CE1 reach inactivation, 30-50% of CE2 and 
CE3 reach inactivation, better response if <6 cm (CE1) and on average 25% reactivate 
after first inactivation. The relapse in less than 1 year is about 50% of those inactivated. 
In the study of follow-up 12 months after albedazole treatment 77% of CE1 and CE3a 
had a response and no response for CE2 and CE3b. These results highly emphasize an 
important role for the WHO-IWGE classification for clinicians in choosing the right 
treatment for individual patients. 
 
Table 1. Comparison of cyst stage by US, light microscopy and MR spectroscopy 
(Hosch et al,, 2007)  
Stages by 
US 
Number of 
samples 
Light microscopy MR spectroscopy 
Viable Non-viable Viable Non-viable 
CE1 7 5 2 6 1 
CE2 8 7 1 8 0 
CE3A 14 6 8 5 9 
CE3B 9 8 1 7 2 
CE4 8 0 8 1 7 
CE5 2 0 2 0 2 
 
 
 
 
! !"
	 	
Presentation from Prof. Thomas Junghanss: 
The main goal of the WHO-IWGE is to find the optimal treatment for patients. 
Therefore the- stage-specific-treatment-options are the nucleus of the WHO-IWGE 
guideline. It was introduced by Prof. Thomas Junghanss, a Head of Section of Tropical 
Medicine in University of Hospital of Heidelberg.  Recently Prof. Junghanss 
appointed for team leader of clinical management of WHO-IWGE (2016). The 
important message at the beginning of the Prof.Junghass presentation was to bring 
the marginal disease, marginal populations in another word neglected diseases to the 
center of health system. However, in many parts of the world proper disease 
management is simply neglected.  Elimination and control of CE can only be achieved 
using a One Health approach, a collaboration between human and animal health 
sectors in order to get added value. 
In Europe, CE has been eliminated in most of countries, due to industrialization 
and development. However, prevalence in imported cases are high due to high 
migrants from endemic region. Therefore clinical management has been progressed 
in the most advanced conditions. Currently in Heidelberg hospital, CE patients are 
managed by a multidisciplinary group. Such technical group would consist of 
ultrasonographist, gastroentereologist, surgeon, anaesthesiologist, nand 
parasitologist.  
Although surgery is considered as the main solution in many countries, the 
management before and after surgery is key to get successful recovery. A 
collaboration between clinicians, radiologists and surgeons is highly efficient in 
treatment and will prevent patient burden substantially. Implementation of stage 
specific treatment with a WHO-IWGE classification system can solve many of the 
issues in terms of health care inequality. Stage specicific treatment is about choosing 
the optimal treatment based on the WHO-IWGE classification. However, there are a 
few exceptions including rare location of the cyst, complicated cyst and disseminated 
cys, which are rare. The following figures are the slides from Prof.Junghanss about 
summary stage specific treatment. 
The screening program is often used to decide on initiating a control program 
and to estimate epidemiologcal burden. It has been implemented extensively in many 
endemic regions. Prof. Junghanss highly emphasized that a plan for management 
needs to be available in advance to offer further diagnosis and management to 
patients in terms of screening.  
In case management, national SOP-based diagnosis and treatment should include 
following essential components: 
• Ultrasound-based treatment decision (à regular course for local GPs to 
optimize case detection and follow-up in local areas including back up 
through telemedicine / smartphones 
• Interdisciplinary management on the basis of agreed and implemented 
SOPs      (à  full integration of CE management into health services 
• Good communication between hospital and family physician (including via 
telemedicine / smartphones) 
• Follow-up yearly for 5 years 
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Presentation from Dr. Bolor Bold 
Dr. Bolor Bold, a PhD candidate from University of Basel and Swiss Tropical and 
Public Health Institute introduced the current project on CE. The local radiologist, 
clinicians active participation, awareness is crucial point for surveillance, control, and 
elimination. During the project, registration at the secondary level with the 
involvement of radiologist could contribute substantially to optimization of clinical 
management.  
 
Hands-On training 
Hands-on training was supervised by Dr. Francesca Tamarozzi and Dr. Erdenebileg 
Bavuujav from Society of Diagnostic Ultrasound and performed with the volunteer 
CE patients.  
 
Prof. Thomas Junghanss and Dr. Francesca Tamarozzi and Dr. Erdenebileg confer on the 
patient image finding while performing US examination  
 
Prof.Thomas Junghanss giving the consultancy on each patients image finding 
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The CE patients under monitoring of Dr. Amgalan Luvsanjav, a head of surgical 
department at First Central Hospital, and Dr. Bat-Ireeui, and Dr. Otgonbayar 
volunteered for examination. In each patient, Dr. Francesca Tamarozzi assisted by Dr. 
Erdenbileg performed US examination with a big screen and the image findings were 
discussed by Dr. Thomas Junghanss.  
 
----------------------------------------------------------------------------------------------- 
 
September 18-19, 2016: Hands-on training of WHO-IWGE classification and control 
in Dalanzadgad city 
 
The team with international experts visited Dalanzadgad city of Omnogobi province to 
conduct hands-on training and workshop of CE with the local professionals. 
 
In the field trip: 
Dr. Erdenebileg Bavuujav, Mongolian Society of Diagnostic Ultrasound,  
Dr. Tsogbadrakh Nyamdorj, National Center for Zoonotic Disease, 
Dr. Shagj Agiimaa, National Center for Zoonotic Disease, 
Dr. Uranshagai Narankhuu, National Center for Zoonotic Disease, 
Dr. Chinchuluun Boldbaatar, Institute of Veterinary Medicine, 
Dr. Bolor Bold, University of Basel 
Dr. Bernadette Abela-Ridder, NTD, World Health Organization 
Prof. Ning Xiao, National Institute of Parasitic Institute 
Prof. Thomas Junghanss, Heidelberg University Hospital 
Prof. Francesca Tamarozzi, Univeristy of Pavia, 
 
From 18-19 of September, the hands-on training of WHO-IWGE and stage-specific-
treatment of CE was held in General Hospital of Dalanzadgad city, organized by CZD 
and NCZD. In the training, the above working group and local health professionals, 
radiologists and family doctors from 20 soums and suspected and diagnosed CE 
patients participated.  
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Dr.Tamarozzi performing US examination  Prof. Junghanss is giving comment on the 
image findings 
 
Dr. Francesca Tamarozzi and Prof. Thomas Junghanss gave presentations about 
WHO-IWGE and Stage specific treatment as presented in FCH on 15 September with 
small modifications for local health professionals. In addition, Prof. Junghanss 
explained the mechanism of percutaneous treatment (PAIR) in CE, and the principle 
of albendazole during follow up period and the common complication of CE. All 
participants received credit hours and certificate. 
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Dr.Erdenebileg is preparing the patients for examination 
 
Table 2. The list of participants for hands –on training, Dalanzadgad, Omnogobi, 18 
September 
№ Name of Soums in Omnogobi  
Participants` 
Name Organization Occupation 
1 Bayan-Ovoo S.Chuluuntogtoh Soum clinic physician 
2 Bayandalai T.Otgonchimeg Soum clinic physician 
3 Bulgan B.Dolgormaa Soum clinic physician 
4 Gurvantes D.Renchin Soum clinic physician 
5 Khabogd J.Narantsetseg Soum clinic physician 
6 Khurmen B.Tuul Soum clinic physician 
7 Mandal-Ovoo Ts.Narmandakh Soum clinic physician 
8 Manlai D.Ulambayar Soum clinic physician 
9 Nomgon B.Batchimeg Soum clinic physician 
10 Noyon Ts.Burmaa Soum clinic pediatrician 
11 Sevrei B.Uyanga Soum clinic physician 
12 Tsogt-Ovoo N.Olz Soum clinic physician 
13 Tsogttsetsii Amartuvshin Soum clinic Surgeon 
14 Dalanzadgad Ravdanjamts  “Khatanzayat” private 
clinic 
US doctor 
15 Dalanzadgad Ch.Bolormaa “Unu-Orshikh” family 
clinic 
physician 
16 Dalanzadgad Gansuvd “Shim bileg” family 
clinic 
physician 
17 Dalanzadgad Enkhmaa General Hospital physician 
18 Dalanzadgad Solongo General Hospital US doctor 
19 Dalanzadgad Tsetsgee  General Hospital physician 
20 Dalanzadgad Enkhtuya “Tegsh duuren” private 
clinic 
US doctor 
21 Dalanzadgad Erdenebayar “Khunleg” private clinic US doctor 
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On 19 September, a workshop held among public and veterinary professionals of 
Dalanzadgad city was organized by Dr. Altanchimeg from CZD and local health 
department. The list of participants is in Table 3. In the workshop, Dr. Bernadette 
Abela-Ridder gave a summary of the vision and goals of World Health Organization 
on Cystic Echinococcosis and Neglected Diseases, Prof. Ning Xiao from NIPD gave a 
presentation about control programs, especially campaigns to raise awareness of 
disease prevention of CE  in Chinese endemic regions.  All participants received credit 
hours and certificate. 
 
 
Dr. Enkhjargal, Head of Health Department in Omnogobi province, opened the workshop 
 
Table 3. Participants of workshop on prevention of CE , Dalanzadgad, Omnogobi 
province, 19 September 
№ Soum* names of Omnogobi  Name Organization 
1 Dalanzadgad D.Buyanbaatar Veterinary Department 
2 Dalanzadgad J.Anhbayar Veterinary Department 
3 Khanbogd B.Nandintsetseg Soum hospital 
4 Khanbogd Ts.Narantuya Soum hospital 
5 Noyon B.Javzan Soum hospital 
6 Noyon Sh.Uyanga Soum hospital 
7 Bulgan E.Byambadelger Health Department 
8 Bulgan Kh.Shinekhuu Health Department 
9 Mandal-Ovoo Duuvee Health Department 
10 Mandal-Ovoo Tserensuren Health Department 
11 Sevrei Bayartsengel Soum hospital 
12 Gurvantes E.Uranchimeg Health Department 
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13 Gurvantes M.Manduukhai Health Department 
14 Dalanzadgad Shurentsetseg Center of Zoonotic Disease 
15 Dalanzadgad Sh.Oyuntuya Center of Zoonotic Disease 
16 Dalanzadgad Chuluundavaa “Iveeh” private clinic 
17 Mandal-Ovoo Ts.Narmandakh Clinic at the soum center 
18 Khabogd J.Narantsetseg Clinic at the soum center 
19 Sevrei B.Uyanga Clinic at the soum center 
20 Dalanzadgad Ch.Bolormaa “Unu-Orshikh” family clinic 
 
 
Dr. Bernadette Abela-Ridder presenting about CE from the WHO perspective. 
 
Prof.Ning Xiao giving presentation about CE awareness raising, IE program in China 
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The team is meeting the Vice  Governer of Omnogobi province.  
 
 
The vice Governer of Omnogobi province Mr. Batbold and Head of Veterinary department, 
Dr. Munkhchuluun and Dr Altanchimeg from CZD at the meeting. 
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Team visited the laboratory of CZD in Omnogobi province 
 
Team visited the laboratories of veterinary health department. The macro specimen at the 
parasitological laboratory.  
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The team in front of CZD in Omnogobi province with director Altanchimeg and her team. 
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